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AIF     apoptosis inducing factor 
Akt     protein-serine/threonine kinase 
Apaf-1     apoptotic protease-activating factor-1 
BH      Bcl-2 homology 
BIR     baculoviral IAP repeat  
c-FLIP   cellular FLICE-inhibitory protein 
DEVD-AFC    DEVD-7-amino-4-trifluoromethyl coumarin 
DFF45    DNA fragmentation factor-45 
DISC     death-inducing signaling complex 
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EGTA     Ethylene Glycol-bi α-aminoethyl Ether 
FLICE     FADD-like interleukin-1beta-converting enzyme 
GrB     granzyme B 
HD B cells    Hodgkin derived B cells 
H-RS     Hodgkin and Reed-Sternberg  
IAP     inhibitor of apoptosis 
LD     lymphocyte depletion 
MHC     major histocompatibility complex 
MC     mixed cellularity 
NS     nodular sclerosis 
OMM     outer mitochondrial membrane 
PBS     phosphate buffered saline 
PI3 Kinase    phosphoinositide 3-OH kinase  
PMSF     Phenylmethylsulfonyl Fluoride 
Smac/DIABLO second mitochondria-derived activator of 
caspases/direct IAP-binding protein with low pI 
TNF Tumour necrosis-factor 
XIAP     X-linked inhibitor of apoptosis  
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Introduction 
 
Apoptosis; Life requires Death. Programmed cell death, or apoptosis, is currently one 
of the most active areas of bio-medicinal research. Apoptosis describes the 
orchestrated collapse of a cell, which manifests in membrane blebbing, cell 
shrinkage, protein processing, chromatin condensation and DNA degradation 
followed by rapid engulfment of corpses by neighbouring cells. Programmed cell 
death has been discovered and rediscovered several times by various developmental 
biologists and cytologists, and has been named differently over the past two 
centuries (Vaux et al. 1996). The term finally adopted is apoptosis, coined by Wyllie 
and colleagues in 1972 to describe a common type of programmed cell death that 
the authors repeatedly observed in various tissues and cell types (Kerr et al. 1972). 
The authors noticed that these dying cells shared many morphological features, 
which were distinct from those observed in cells undergoing necrotic cell death, and 
they suggested that these shared morphological features might be the result of an 
underlying common, conserved, endogenous cell death programme (Wyllie et al. 
1980) (Fig. 1). 
Apoptosis is an essential part of life for any multicellular organism. It is necessary to 
purge the body of pathogen-infected cells, to shape the organs during development, 
but it is also needed to eliminate activated or auto-aggressive immune cells. 
Apoptosis has to be tightly regulated because too little or too much of cell death may 
lead to pathologic phenomena, including developmental defects, autoimmune 
diseases, neurodegeneration or cancer. 
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Fig. 1. Apoptosis or cell suicide. Upon apoptosis cells activate an intracellular death program and 
kill themselves in a controlled way. In contrast to necrotic cells, apoptotic cells shrink and form 
apoptotic bodies, which are rapidly up taken by neighbouring cells, before there is any leakage of their 
contents (Willie et al. 1980).  
 
Central effectors of apoptosis. Apoptosis, the regulated destruction of a cell, is a 
complicated process. The decision to die depends on the activity of many molecules 
that determine a cell's likelihood of activating its self-destruction programme. Most of 
the specific morphological changes that were observed in apoptotic cells are caused 
by a set of cystein proteases upon apoptotic stimuli. These death proteases are 
homologous to each other, and are part of a large protein family known as caspases 
(Alnemri et al. 1996). Caspases are highly conserved throughout evolution, and can 
be found from humans to insects, nematodes and hydra (Budihardjo et al. 1999, 
Cikala et al. 1999 and Earnshaw et al. 1999). Over a dozen caspases have been 
identified in humans, and most of these have been suggested to fulfill distinct 
functions in apoptosis (Thornbery et al. 1998 and Rano et al. 1997). 
All caspases are cystein containing aspartate-specific endoproteases. Caspases 
display distinct substrate specificity, determined by the four residues amino-terminal 
Apoptosis
Necrosis
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to the cleavage site  (Asp-Xxx ).  Caspases are activated upon various apoptotic 
stimuli that occur via cleavage of the proenzyme at a specific aspartate, which is 
followed by the dimerization of cleaved products to generate the active enzyme 
(Alnemri et al. 1997). The active enzyme can then cleave numerous cellular proteins 
necessary for cellular homeostasis and results in the typical morphological hallmarks 
of apoptosis (Thornbery et al. 1998).  
 
Two apoptotic signaling pathways. Two major distinct apoptotic signaling pathways 
have been identified (Fig. 2). The first route can be initiated by the oligomerization, 
most probably the trimerization,  of tumor necrosis factor receptor (TNF-R) family 
members, such as CD95, induced by ligation of their specific ligand. Receptor 
oligomerization results in formation of a complex of proteins associated with activated 
receptors. The so-called death-inducing signaling complex (DISC) is the first initiator 
complex after apoptotic induction. The death signal is propagated by a caspase 
cascade initiated by the activation of caspase-8, also called FLICE (FADD-like 
interleukin-1beta-converting enzyme), at the DISC followed by a rapid cleavage of 
executioner caspases, like caspase-3 and other caspases, which eventually cleave 
vital substrates in the cell (Krammer 2000, Krammer 1999, Kischkel et al. 1995, Peter 
et al. 1998, Muzio et al. 1996, Scaffidi et al. 1998 and Ashkenazi et al. 1999). The 
second apoptotic signaling pathway involves mitochondria. The mitochondrial 
apoptotic pathway is normally activated intrinsically. For example DNA damage can 
activate the mitochondrial apoptotic pathway through an unknown p53 dependent 
mechanism without the use of death receptors (Dubrez et al. 2001 and Henry et al. 
2002). Once this pathway is activated, the mitochondria release pro-apoptotic factors 
from its intermembrane space, such as cytochrome c (Reed et al. 1998 and 
Jürgensmeier et al. 1998). The released cytochrome c together with the apoptosis 
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protease-activating factor (Apaf-1) and procaspase-9 in the cytoplasm forms the 
apoptosome, the other initiator complex of apoptosis (Li et al. 1997 and Saleh et al. 
1999). This apoptosome complex in turn activates downstream executioner 
caspases, like caspase-3, -6 and -7 (Li et al. 1997, Reed et al. 1998 and Green et al. 
1998). In addition, activated caspase-8 can also cleave Bid, a member the pro-
apoptotic Bcl-2 family. Cleavage of Bid greatly increases its pro-death activity, and 
results in translocation of Bid to mitochondria, where it promotes cytochrome c 
release (Hengartner 2000).  In most situations, the cross-talk between the death-
receptor and mitochondrial pathways is minimal and probably depends on the 
amount of caspase-8 (Krammer 2000), therefore the two pathways operate largely 
independently of each other (Hengartner 2000, Gross et al. 1999-a and Yin et al. 
1999).  
 
Fig. 2. Apoptotic pathways in mammalian cells.  
The death-receptor pathway is triggered by members of the death-receptor superfamily (such as CD95 
and tumour necrosis factor receptor I). Binding of CD95 ligand to CD95 induces receptor clustering 
and formation of the DISC. The DISC recruits multiple procaspase-8 molecules, resulting in caspase-8 
processing and activation. Caspase-8 activation can be blocked by recruitment of the caspase 
homologue c-FLIP (cellular FLICE-inhibitory protein) (Irmler et al. 1997). The mitochondrial pathway is 
used extensively in response to extracellular cues and internal insults such as DNA damage. These 
diverse response pathways converge on mitochondria, often through the activation of a pro-apoptotic 
member of the Bcl-2 family, such as Bid. Pro- and anti-apoptotic Bcl-2 family members meet at the 
surface of mitochondria, where they compete to regulate cytochrome c release by a mechanism that is 
still debated. If the pro-apoptotic proteins are dominant, an array of molecules is released from the 
mitochondrial compartment. Principal among these is cytochrome c, which associates with Apaf-1 and 
then procaspase-9 (and possibly other proteins) to form the apoptosome. The death-receptor and 
mitochondrial pathways converge at the level of caspase-3 activation. Downstream of caspase-3, the 
apoptotic programme branches into a multitude of subprogrammes, the sum of which results in the 
ordered dismantling and removal of the cell. 
Cross-talk and integration between the death-receptor and mitochondrial pathways is provided by Bid, 
a pro-apoptotic Bcl-2 family member. Caspase-8-mediated cleavage of Bid greatly increases its pro-
death activity, and results in its translocation to mitochondria, where it promotes cytochrome c release. 
Additional death-inducing pathways are mediated by granzyme B, which enters the cells through a 
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pore-forming protein, perforin. Cytosolic granzyme B can then promote both, mitochondrial mediated 
or direct activation of caspase-3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The mitochondrion in apoptosis. The mitochondrion is not only the cell's powerhouse, 
it is also its arsenal. The mitochondrion acts as a pivotal decision center in many 
types of apoptotic responses, because it releases death-promoting factors from its 
intermembrane space into the cytosol. Release of cytochrome c from mitochondria 
couples these organelles to a pathway for caspase activation and apoptosis induction 
(Reed et al. 2000 and Matsuyama et al. 2000). Cytochrome c, which normally 
shuttles electrons between protein complexes of the respiratory chain in the 
mitochondria, can trigger formation of the apoptosome in the cytoplasm in the 
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presence of dATP. Apoptosis is therefore depending on ATP production. If 
mitochondria are damaged and fail to produce ATP early during apoptosis, the 
apoptosome can not form, and caspase-9 is not activated and cells die by necrosis. 
This emphasizes the pro-apoptotic role of functional mitochondria (Desagher et al. 
2000, Nicotera et al. 1999 and Chautan et al. 1999). Cytochrome c is only one of the 
mitochondrial pro-death molecules. Also present in mitochondria and released upon 
induction of apoptosis are Smac/DIABLO, which antagonizes the inhibitory effect of 
the inhibitors of apoptosis (IAP) (Du et al. 2000 and Verhagen et al. 2000), apoptosis 
inducing factor (AIF), a flavoprotein with potent but relatively mysterious apoptotic 
activity (Lorenzo et al. 1999) and Omi/HtrA2, a serin protease which interacts and 
inhibits the X-linked inhibitor of apoptosis (XIAP) and enhances caspase activity 
(Hegde et al. 2002). 
The outer mitochondrial membrane (OMM) becomes permeable to apoptogenic 
factors through different apoptotic stimuli. Permeabilization of the OMM is controlled 
by members of the Bcl-2 family (Desagher et al. 2000). 
 
Bcl-2 family, regulators of apoptosis. Each step of the apoptotic signaling cascade is 
under stringent control. Important regulators of apoptotic signaling are the proteins of 
the Bcl-2 family. This protein family was named after the founding member of the 
family, which was isolated as a gene involved in follicular B cell lymphoma (Tsujimoto 
et al. 1985). The Bcl-2 family is comprised of well over a dozen proteins, which have 
been classified into three functional groups (Adams et al. 1998, Antonsson et al. 
2000 and Hengartner 2000). Members of the first group, such as Bcl-2 and Bcl-xL, 
are characterized by four short, conserved Bcl-2 homology (BH) domains (BH1–BH4) 
(Fig. 3). They also possess a C-terminal hydrophobic tail, which localizes the proteins 
to the outer surface of mitochondria, and occasionally of the endoplasmic reticulum 
  Introduction 
 7
(Foyouzi-Youssefi et al. 2000 and Hacki et al. 2000), with the bulk of the protein 
facing the cytosol (Reed et al. 1998). The key feature of group I members is that they 
all possess anti-apoptotic activity and protect cells from death. In contrast, group II 
consists of Bcl-2 family members with pro-apoptotic activity. Members of this group, 
which includes Bax and Bak, have a similar overall structure to group I proteins, 
containing the hydrophobic tail and all but the most N-terminal, BH4 domain (Adams 
et al. 1998 and Antonsson et al. 2000). Structure/function studies suggest that anti- 
versus pro-apoptotic activity is determined by relatively large regions of the protein, 
including two large α-helices that have been proposed to participate in membrane 
insertion. Group III consists of a large and diverse collection of proteins, whose only 
common feature is the presence of the 12–16-amino-acid BH3 domain (Adams et al. 
1998). Although some members of group III, including Bid, are indeed divergent 
homologues of Bcl-2 and Bax (McDonnell et al. 1999 and Chou et al. 1999), others 
share little sequence or structural similarity with group I and II, suggesting that the 
BH3 domain in these proteins has arisen through convergent evolution (Gross et al. 
1999-b). Classification of such proteins as Bcl-2 family members is thus more a 
matter of convenience than a statement of presumed evolutionary relationship 
(Hengartner 2000). 
 
Fig. 3. Bcl-2 family protein.  
The Bcl-2 family is comprised of well over a dozen proteins, which have been classified into three 
functional groups. Members of the first group, such as Bcl-2 and Bcl-xL, are anti-apoptotic and 
characterized by four short, conserved Bcl-2 homology domains and a C-terminal hydrophobic tail. In 
contrast, group II consists of Bcl-2 family members with pro-apoptotic activity, including Bax and Bak, 
have a similar overall structure to group I proteins, but the most N-terminal, BH4 domain. Group III 
consists of a large and diverse collection of proteins, including Bid and Bik, whose only common 
feature is the presence of the 12–16-amino-acid BH3 domain.  
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How do Bcl-2 family members regulate cell death? Many Bcl-2 family members can 
homodimerize, but more importantly, pro- and anti-apoptotic members can form 
heterodimers (Adams et al. 1998, Antonsson et al. 2000 and Reed 1997). To a first 
approximation, heterodimerization can simply be thought as resulting in mutual 
neutralization of the bound pro- and anti-apoptotic proteins. Thus, cells with more 
pro-death proteins are sensitive to death, cells with an excess of protective family 
members are usually resistant (Hengartner 2000). 
Based on the structural similarity of Bcl-xL to the pore-forming subunit of diphtheria 
toxin (Muchmore et al. 1996), it has been suggested that Bcl-2 proteins might act by 
undergoing a conformational change, followed by insertion into the outer 
mitochondrial membrane, where they could form channels or even large pores 
(Hengartner 2000). Bcl-2 family members indeed can insert into synthetic lipid 
membrane and mitochondrial outer membrane, oligomerize, and form channels with 
discrete conductances (Reed 1997).  
One of the most investigated molecular cross talks among the Bcl-2 family proteins is 
the Bid-mediated oligomerization of Bax and Bak (Wei et al. 2001, Wei et al. 2000 
and Korsmeyer et al. 2000). The connection and integration between the death-
receptor and mitochondrial pathways is apparently provided by Bid. Caspase-8 
Group Bcl-2/Bcl-XL
Group Bax/Bak 
Group 
Bik 
Bid 
BH4 BH3 BH1 BH2 TM
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mediated cleavage of Bid greatly increases its pro-death activity and results in its 
translocation to mitochondria, where Bid either promotes cytochrome c release 
directly (Zhai et al. 2000 and Kim et al. 2000) or via interaction with other pro-
apoptotic Bcl-2 proteins such as Bax and Bak. Cleaved Bid binds to Bax and Bak and 
stimulates an allosteric activation of these molecules resulting in oligomerization and 
formation of the proposed pores for cytochrome c efflux (Wei et al. 2000, Desagher et 
al. 1999 and Eskes et al. 2000).  
 
Conformational change of Bax: a question of life or death. Bax is a pro-apoptotic Bcl-
2 protein that in healthy cells is ‘dormant’, located in the cytosol or loosely associated 
with mitochondria (Roucou et al. 2001). Upon induction of apoptosis, Bax can induce 
the release of cytochrome c from mitochondria and represents an important relay of 
the mitochondrial apoptotic pathway and subsequent activation of caspases (Kluck et 
al. 1997, Reed et al. 1998 and Jürgensmeier et al. 1998). In order to induce 
cytochrome c release, Bax moves from the cytosol to the mitochondria, undergoes a 
conformational change, leading to exposure of its N- and C-termini which appears to 
be required for insertion into the mitochondrial outer membrane. Allosteric activated 
Bax can now form oligomers and gain its pro-apoptotic activity (Wolter et al. 1997, 
Nechushtan et al. 1999 and Murphy et al. 2000). The recent resolution of the 3D 
structure of full length monomeric Bax has brought new insights into the requirement 
for structural modifications but the underlying mechanisms for the conformational 
change and the activation of Bax are not yet known (Fig. 4).  
 
Fig. 4. Mitochondrial apoptotic pathway. Bax, either cytosolic or loosely associated with 
mitochondria (1), undergoes a conformational change upon apoptotic stimulation. The conformational 
change leads to exposure of its N- and C-termini with subsequent insertion in the mitochondrial outer 
membrane. Only the relaxed, flexible N-termius of Bax in its new conformation can be detected by 
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mouse anti-Bax 6A7 (2). Allosteric activated Bax can now form oligomers (3) and promote release of 
apoptotic proteins, such as cytochrome c and Smac/DIABLO (4). Cytosolic cytochrome c induced 
Apaf-1 oligomerization, which in turn induces recruiting and processing of pro-caspase-9 (p46) in the 
apoptosome by an intrinsic autocatalytic activity of procaspase-9 itself, generates active caspase-9 
(p35) (5). Active caspase-9 cleaves and activates procaspase-3 (p32) generating the large (p24) and 
small (p12) subunits (6). Autocatalytic processing of p24 subunit of caspase-3 occurs in two sequential 
steps, removing its own prodomain generating the mature p17 fragment (7). The initiation of the 
caspase cascade by the apoptosome can be inhibited by XIAP at two distinct levels, at the level of 
caspase-9 activation and at the level of caspase-3 activation by inhibiting the autocatalytical 
processing. The inhibitory effect of XIAP can be abrogated by cytosolic Smac. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Apoptotic signaling downstream of mitochondria. A critical step in the induction of the 
caspase cascade downstream of mitochondria is the activation of the apoptotic 
initiator caspase-9. How the formation of the apoptosome complex leads to caspase-
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9 activation is not yet clear but it might be induced by dimerization which is mediated 
by multimeric Apaf-1 complex (Acehan et al. 2002 and Renatus et al. 2001). Apaf-1 
induces processing of procaspase-9 by an intrinsic autocatalytic activity generating 
active caspase-9 (Srinivasula et al. 1998) (Fig. 4). Once activated, caspase-9 can 
initiate a caspase cascade involving downstream executioners such as caspase-3, -
6, and -7. Caspase-3 is expressed in cells as an inactive 32-kDa precursor from 
which the 17-kDa and 12-kDa subunits of the mature caspase-3 are proteolytically 
generated during apoptosis (Han et al. 1997). The processing of caspase-3 occurs in 
two steps, beginning with a cleavage by other site specific proteases between what 
will be the large and small subunits. Following this cleavage, the large domain of 
caspase-3 removes its own prodomain in two sequential steps generating the mature 
p17 fragment (Martin et al. 1996, Deveraux et al. 1999-a, Deveraux et al. 1998, 
Deveraux et al. 1997 and Fernandes-Alnemri et al. 1996). 
 
Regulation of caspase activation. The function of the caspases is modulated by a set 
of proteins, the IAPs (inhibitor of apoptosis) (Deveraux et al. 1999-b). The IAP gene 
products play an evolutionary conserved role in regulating apoptosis in diverse 
species ranging from insects to humans (Deveraux et al. 1998). Members of the IAP 
family, originally identified in baculoviruses (Crook et al. 1993), contain one or more 
modules called baculoviral IAP repeat (BIR) (Deveraux et al. 1999-b). Some family 
members also contain a C-terminal RING finger through which they are targeted for 
ubiquitination and subsequent proteolysis (Huang et al. 2000).  
One of these, XIAP, binds to and inhibits the protease activity of caspase-9, and 
thereby blocks the apoptotic process at this point (Deveraux et al. 1998). It also binds 
to and inhibits caspase-3 and –7, but not caspase-8 (Takahashi et al. 1998 and Riedl 
et al. 2001). Caspase binding and inhibition is mediated by the BIR domains of IAPs, 
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which are necessary and sufficient for their function. The inhibition of caspase-3 by 
XIAP has an unique characteristic. If XIAP inhibits caspase-3, the first cleavage can 
occur but the second will not, due to the inhibition of caspase-3 activity (Deveraux et 
al. 1999-a, Deveraux et al. 1998 and Deveraux et al. 1997 and Fernandes-Alnemri et 
al. 1996). The removal of the prodomain is not required for caspase-3 activity, but 
this partial cleavage might serve as a ''footprint'' of XIAP inhibition of caspase-3 
function (Deveraux et al. 1999-a, Deveraux et al. 1998, Deveraux et al. 1997 and 
Green 2000). The RING domain of XIAP acts as an ubiquitin ligase and promotes the 
degradation of XIAP and any caspase bound to it. Highly expressed XIAP can 
promote ubiquitination and proteosomal degradation of active-form of caspase-3 and 
enhances its anti-apoptotic effect (Suzuki et al. 2001). In summary, XIAP, and 
probably other IAP molecules, block the apoptotic process by binding, inhibiting, and 
degrading caspases. 
Additional regulation is provided by Smac (second mitochondria-derived activator of 
caspases) or its murine homolog DIABLO (direct IAP-binding protein with low pI), 
which binds to IAPs and abrogates caspase inhibition (Du et al. 2000 and Verhagen 
et al. 2000). The proform of Smac contains a N-terminal sequence that targets this 
protein to the intermembrane space of mitochondria. Upon induction of apoptosis, 
Smac is released into the cytosol together with cytochrome c and modulates 
apoptosis (Verhagen et al. 2000 and Stephan et al. 2001). In addition to regulation of 
apoptosis-associated mitochondrial cytochrome c release, Bcl-2 family proteins also 
regulate the Smac release, suggesting that both molecules may escape via the same 
route (Adrain et al. 2001, Deng et al. 2002 and Roucou et al. 2001).  Smac promotes 
apoptosis through at least two mechanisms: by inducing the proteolytic activation of 
procaspase-3 and by promoting the enzymatic activity of mature caspase-3. Both 
functions depend on the ability of Smac to interact physically with IAPs. The N-
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terminal residues of Smac share significant homology with the conserved class of 
IAP-binding motifs (Srinivasula et al. 2001). It is likely that the N-terminus of the 
Smac protein simply displaces the bound caspase and releases the activated 
enzyme (Adrain et al. 2001 and Chai et al. 2000) (Fig. 4 and 5).  
 
Fig. 5. Inhibition of the caspase cascade in the apoptosome by XIAP. 
Apaf-1 forms a cytochrome c/dATP dependent oligomer and recruits procaspase-9 (p46) to the 
apoptosome and promotes capase-9 autocatalytic activity. Caspase-9 in a complex with Apaf-1 
recruits caspase-3 and promotes its initial cleavage followed by its autocatalytical processing. XIAP is 
also attracted to the apoptosome and can bind to and inhibit caspase-9 through its BIR3 domain. It 
can simultaneously bind to and inhibit caspase-3. The binding to caspase-3 is mediated by LP (linker 
peptide) part of XIAP, which binds to the catalytic groove of caspase-3 and might provide allosteric 
inhibition for the substrate binding site of caspase-3, which requires BIR1/2 domains. Additional 
regulation is provided by Smac, which binds to XIAP and abrogates caspase inhibition. Smac 
promotes caspase-3 activation through two mechanisms: promoting caspase-9 activation which leads 
to initial cleavage of caspase-3, and promoting the caspase-3 proteolytic activity which leads to 
maturation of caspase-3 generating the proteolytically active p17 fragment. 
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Granzyme B as an initiator and executioner of apoptosis. Whereas some cytotoxic T 
lymphocytes kill their target cells by turning on the death receptor, others use perforin 
and granzyme B (GrB). The major mechanism of cytotoxic lymphocyte killing involves 
the directed release of granules containing perforin and a number of proteases onto 
the target cell membrane. One of these proteases, GrB, has an unusual substrate 
site preference for Asp residues, a property which is shared with members of the 
caspase family (Martin et al. 1996). With the help of perforin, GrB finds its way into 
the target cell and can kill it by 1) cleaving and activating caspase-8 (Medema et al. 
1997), 2) cleaving caspase-3 between the large and small subunits of proenzyme 
and converting it to its active form (Martin et al. 1996 and Fernandes-Alnemri et al. 
1996), 3) cleaving of Bid and activation of mitochondrial apoptotic pathway (Heibein 
et al. 2000, Sutton et al. 2000 and Pinkoski et al. 2001), or 4) caspase-independent 
direct cleavage of death substrates, such as the human DNA fragmentation factor-45 
(DFF45) (Sharif-Askari et al. 2001) (Fig. 2). 
 
Cancer is a disease of deregulated Apoptosis. Cancer is a plethora of conditions 
characterized by unscheduled and uncontrolled cellular proliferation. The causes of 
cancer are many and varied, and include genetic predisposition, environmental 
influences, infectious agents and ageing. In almost all instances, deregulated cell 
proliferation associated with suppressed apoptosis provide the underlying platform for 
neoplastic progression and carcinogenesis (Evan et al. 2001). The study of the 
molecular basis of apoptosis is leading to the discovery of molecular cross talks, 
some of which are already used in clinical trials, and promise for more refined and 
more effective cancer therapies.  
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Discovery of Reed-Sternberg cells. In 1832, Thomas Hodgkin (Hodgkin 1832) 
described the anatomic findings of seven patients with enormous lymph node 
swellings. Independently, Samuel Wilks published an article in 1856 summerizing ten 
cases having the same anatomic features (Wilks 1856). In the following years, Wilks 
collected additional 15 cases and interpreted them as pathognomonic for a new 
disease entity (Wilks 1865). Although it was Wilks who separated Hodgkin’s disease 
from other diseases associated with lymph node swellings, he was sufficiently 
magnanimous to name the disease after Hodgkin in acknowledgment of Hodgkin’s 
first report of some cases. In 1898, Carl Sternberg (Sternberg 1898) and in 1902, 
Dorothy Reed (Reed 1902) published, independently of each other, a more detailed 
description of the cytological features of the multinucleated giant cells, which have 
since been known as Reed-Sternberg cells. The mononucleated blasts were later 
designated Hodgkin cells. Combined histological and immunohistological studies of 
the last 25 years characterized Hodgkin and Reed-Sternberg cells (H-RS) as a 
distinct immunotype of atypical blasts in Hodgkin’s disease with constant expression 
of CD30, frequent expression of CD15, and constant absence of the J chain of 
immunoglobulin. In view of these findings, the international Lymphoma Study Group 
proposed to subsume all Hodgkin’s disease histotypes with this distinct immunotype, 
including nodular sclerosis (NS), mixed cellularity (MC), and lymphocyte depletion 
(LD), under the generic term classical Hodgkin’s disease (Harris et al. 1994 and 
Mauch et al. 1999). 
 
Permanent Hodgkin’s disease cell lines. Because H-RS are rare in the tissues 
affected by Hodgkin’s disease, research has been hampered for decades. 
Immunohistological methods allowed the specific detection of certain molecules in 
the tissues at the single-cell level but for functional analysis and crosstalks between 
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different molecules permanent cell lines are needed. Attempts were made to 
establish permanent cell lines derived from Hodgkin and Reed-Sternberg cells in last 
30 years. The first permanent cell line, designated L428, was established in Diehl’s 
laboratory in 1979 (Schaadt et al. 1979). The L428 line was established from a 
patient with advanced-stage Hodgkin’s disease and grew out from a pleural effusion. 
All additional cell lines were also established from body fluids (bone marrow, pleural 
effusion and peripheral blood) of patients with advanced-stage disease (Table 1, 
materials and methods). These cell lines resemble in situ H-RS cells as confirmed by 
i) morphology, ii) ability to bind T cells to form rosettes, iii) expression of major 
histocompatibility complex (MHC) class II molecules, and iv) the absence of 
immunoglobulin and macrophages characteristic enzymes (Mauch et al. 1999). 
 
Aim of the work. Apoptosis in the immune system is a fundamental process 
regulating lymphocyte maturation, receptor repertoire selection and homeostasis. 
Death by apoptosis is as essential for the function of lymphocytes as growth and 
differentiation. The ability to avoid apoptosis is one of the keys to cancer cell survival 
and expansion. The Reed-Sternberg cell of Hodgkin’s disease (H-RS)  is a malignant 
germinal center B cell with rearranged but nonproductive immunoglobulin genes 
(Küppers et al. 1998 and Cossman et al. 1999). However, through yet unknown 
mechanisms, H-RS cells resist the apoptotic fate normally suffered by defective B 
cells with crippled immunoglobulin genes. Four Hodgkin derived B cell lines (HD B 
cell lines) uniformly proved resistant to apoptosis induced by CD95L (Re et al. 2000) 
suggesting the existence of defective apoptotic pathways in these cell lines. While 
emerging evidence suggests a proximal defect in CD95 signaling in H-RS cells due 
to c-FLIP (Thomas et al. 2001) little is known about possible defects of mitochondrial 
apoptotic pathway. This work is focused on the mitochondrial apoptotic pathway, and 
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aimed to unravel the intracellular mechanisms that contribute to resistance to 
apoptosis. HD B cell lines were stimulated with staurosporine, that induces apoptosis 
selectively involving the intrinsic mitochondrial pathways. Special emphasis was 
devoted to the action of Bcl-2 family members and the apoptosome, in order to obtain 
new insights into possible molecular defects up- and downstream of mitochondria. 
The detailed analysis revealed two distinctive defects in mitochondrial apoptotic 
pathway in Hodgkin and Reed-Sternberg cells at the level of activation of Bax, 
upstream of mitochondria, and caspase activation, downstream of mitochondria.  
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Materials and Methods 
 
Cell culture 
The establishment of the Hodgkin B-cell lines L591, L428, L1236 and KMH2 has 
been described elsewhere (Schaadt et al 1979, Diehl et al 1982, Kanzler et al 1996 
and Kamesaki et al 1986) (Table 1). The control B cell lines were established by 
immortalisation of human primary B cells by EBV. The cell lines were cultured in VLE 
RPMI 1640 (Biochrom) supplemented with 10% FCS (Biochrom), 2 mM L-glutamine, 
100 µg/ml streptomycin and 100 U/ml penicillin. Apoptosis was induced by incubating 
the cells in the presence of 1 µM staurosporine (Alexis). Cell death was examined 
using trypanblue exclusion. All chemicals were purchased from Sigma unless 
indicated otherwise. 
 
Table 1. Immunophenotype and genotype of cell lines established from tissues affected with 
Hodgkin’s disease.      
Cell 
lines 
CD30 CD70 CD15 CD68 B-AG T-AG rearanged 
gene 
chain 
Expression 
EBV 
L428 + + + - - - IgH, L - - 
L591 + + +/- - CD19, 20 CD2 IgH, L IgAλ + 
L1236 + + + - - - IgH, L - - 
KMH2 + + + - - - IgH, L - - 
CD: cluster of differentiation, AG: Antigen, EBV: Epstein Barr virus, Ig: Immunoglobulin,  
 
- The HD B cell lines and L1309, L1311 were a gift of Prof. Dr. V. Diehl, 
University of Köln, Germany.  
- LCL6 control B cell line was a gift of Dr. M. Kochanek, University of Köln, 
Germany.  
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- C28 control B cell line was a gift of Dr. H. Abken,  University of Köln, 
Germany. 
 
Sample Preparation and Immunoblotting 
For isolation of cytosolic extracts for western blot analysis, 107 cells were washed 
twice with PBS at 4 °C. Cells were resuspended in 50 µl of buffer A  and 1 mM 
dithiothreitol and incubated for 20 min on ice for swelling. After addition of mannitol 
and sucrose to a final concentration of 220 mM and to 68 mM respectively, cells were 
cracked by passing through a 27-gauge needle. Cell breakage was verified 
microscopically using trypanblue exclusion. Membranes were pelleted at 14,000 x g 
for 20 min at 4 °C, and the resulting supernatants recovered (cytosolic extract). 
Whole cell extracts were prepared by lysing 107 cells in 1 ml of CHAPS lysis buffer 
on ice for 30 min. The crude lysate was then centrifuged at 14,000 x g for 20 min at 
4 °C and the supernatant stored at -80 °C. Equal volumes of cytosol and whole cell 
extract (same cell number) were separated by SDS-PAGE and transferred to 
nitrocellulose membrane (Protran 0.2 µm; Schleicher and Schuell). Blots were 
incubated with Blocking buffer for 30 min. and subsequently incubation with primary 
antibodies shown in table 2. Horseradish peroxidase conjugates of anti-rabbit and 
anti-mouse IgG (Biorad) were used as secondary antibodies and signals were 
detected by ECL (Amersham). 
 
- Polyclonal anti-sera specific for Bcl-2 and Bcl-XL were a gift from Dr. John C. 
Reed, La Jolla, USA. 
- Polyclonal anti-serum specific for caspase-9 was a gift from DR. Guy Salvesen 
La Jolla, USA. 
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Table 2. Antibodies used in western blotting. 
antigen isotype immunogene supplier dilution Catalog No. 
hApaf-1 polyclonal/rabbit aa 12-28 BD Pharmingen 1/2000 559683 
m,hβactin monoclonal/mouse N-terminal 16 aa Sigma 1/5000 A-5541 
h,m,rBak polyclonal/rabbit aa 14-33 BD Pharmingen 1/2000 65401A 
hBax polyclonal/rabbit aa 43-61 BD Pharmingen 1/2500 13666E 
hBcl-2 polyclonal/rabbit - Dr. JC Reed 1/2500 - 
hBcl-XL polyclonal/rabbit - Dr. JC Reed 1/2500 - 
Caspase-3 polyclonal/rabbit full length BD Pharmingen 1/4000 556425 
Caspase-9 polyclonal/rabbit - Dr. G. Salvesen 1/3000 - 
Cytochrome c monoclonal/mouse aa 1-80, 66-104 BD Pharmingen 1/2500 556433 
hSmac polyclonal/rabbit aa 199-212,226-
239 
Alexis 
Biochemicals 
1/1500 210-788-c100
hILP/XIAP monoclonal/mouse aa 268.426 BD Transduction 
lab. 
1/2500 H62120 
aa: amino acid, h: human, m: mouse, r: rat 
 
Table 3. Reagents for western blotting 
CHAPS lysis buffer 10 mM HEPES, pH 7.4, 150 mM NaCl, 1% CHAPS, protease complete 
cocktail 
Buffer A 50 mM PIPES, pH 7.0, 50 mM KCl, 2 mM MgCl2, 5 mM EGTA, 10 µM 
cytochalasin B, protease complete cocktail (15 µg/ml pancreatic extract; 15 
µg/ml pronase; 0.8 µg/ml thermolysin; 1.5 µg/ml chymotrypsin; 0.2 mg/ml 
trypsin; 1 mg/ml papain;  Roche Diagnostics) 
5x loading buffer 60 mM Tris-HCl (pH 6,8), 14,4 mM SDS, 25% Glycerol solution, 1% 
Bromphenol blue 
10x Running buffer 3% Tris base, 14,4 Glycine, 1% SDS 
Transfer buffer 25 mM Tris/Glycine, 20% Methanol and 0.05% SDS pH 8,3 
10xWashing buffer 
(STAN PBS)  
1,2 M NaCl, 0,1 M NaH2PO4, 0,3 M K2HPO4 pH7,6 
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Immunoprecipitation of activated Bax 
Equal volumes of whole CHAPS cell lysates (107 cells/ml) were used for 
immunoprecipitation. The KCl concentration of the cell lysates was adjusted to 
150 mM, and all samples were brought to a final volume of 500 µl with CHAPS lysis 
buffer. Samples were rotated for 12 h at 4 °C with 6 µg of monoclonal anti-Bax 6A7 
antibody. Antigen-antibody complexes were immobilized by rotation for 2 h at 4 °C 
with GammaBind G Sepharose (Pharmacia Biotech). The complexes were pelleted (1 
min, 14000 g) and the supernatant removed. The complexes were then washed 3 
times with the same buffer used for the immunoprecipitation at 4°C and subjected to 
SDS-PAGE and immunoblotted as described above. 
 
Table 4. Antibodies for immunoprecipitation. 
antigen isotype immunogene supplier Catalog No. 
h,m,rBax monoclonal/mouse (6A7) aa 12-24 BD Pharmingen 66241A 
 
Immunofluorescence and Fluorescence Microscopy 
Cells were treated with 1 µM staurosporine for 0, 2, 4, 6 and 12 h, harvested and 
washed twice with cold PBS. Cells were then fixed with 3 % paraformaldehyde in 
PBS for 20 min, permeabilized in washing buffer for 10 min, and blocked with 
blocking buffer for 30 min. For immunostaining, cells were incubated with primary 
mouse anti-Bax 6A7 antibody for 1 h, washed 3x with washing buffer and then 
incubated with goat anti-mouse antibody conjugated with Alexaflour 568 (Molecular 
Probes) (diluted: 1/1000) for 30 min. Nuclei were counterstained with Hoechst 33258 
(Sigma) (10 µg/ml PBS) and mounted on glass slides and examined under a 
fluorescence microscope. 
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Table 5. Antibodies for Immunofluorescence  
antigen isotype immunogene supplier dilution Catalog No. 
h,m,rBax monoclonal/mouse 
(6A7) 
aa 12-24 BD Pharmingen 1/1000 66241A 
 
Table 6. Reagents for Immunofluorescence staining 
Blocking buffer 0.1% Saponin, 3% BSA (fraction V), 4 µl/ml Gelatine (Teleostean Gelatine) in 
PBS 
Washing buffer 0.1 % Saponin in PBS 
 
Preparation of cytosolic extracts and caspase activation 
For preparation of cell free lysates the procedure described by Ellerby et al., 1997, 
and Stennicke et al., 1998 was used with minor modifications. Cells were harvested, 
washed twice in phosphate-buffered saline at 4 °C, pelleted for 5 min at 1200 g, 
resuspended in HEB and allowed to swell on ice for 20 min. After addition of PMSF 
to 100 µM, cells were cracked by passing through a 27-gauge needle and pelleted at 
14,000 x g for 20 min at 4 °C. The resulting supernatant (cytosolic extract) was 
recovered. Protein concentration was determined by the bicinchroninic acid assay 
method (Pierce) using BSA as a standard and were adjusted to 20 mg/ml.  
Caspase activation by exogenously added cytochrome c/dATP. 10 µM horse heart 
cytochrome c together with 1 mM dATP, were added to 20 µl of cell extracts and 
incubated for 1 h at 30°C. 
Caspase activation by exogenously added caspase-8. 100 nM of purified 
recombinant active caspase-8 (Stennike et al 1997) was added to 20 µl of cell 
extracts or HEB as a control and incubated for 1 h at 30°C.  
Caspase activation by exogenously added granzyme B. 60 µg granzyme B (Sigma) 
was added to 20 µl of cell extracts or HEB as a control and incubated for 1 h at 30°C.  
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Caspase activation by cytochrome c/dATP and further addition of Smac. 1 µM 
recombinant Smac protein without the mitochondrial targeting sequence together 
with 10 µM horse heart cytochrome c and 1 mM dATP were added to 20 µl of cell 
extracts and incubated for 1 h at 30°C. 
Proteolytic activity of exogenously added mature caspase-3. 100 ng (1µl) 
recombinant active caspase-3 (BD Bioscience) was added to 40 µg (1µl) cytosolic 
extract or 1 µl of HEB and pre-incubated for 15 min. on ice followed by 30 min. 
incubation at 30°C. 
1 µl of resulting cytosolic extracts and HEBs were added to 99 µl caspase buffer and 
reactions were initiated by addition of 100 µM Ac-DEVD-AFC (Ac-DEVD-7-amino-4-
trifluoromethyl coumarin) (Stennicke et al 1997). Caspase activity was assayed by 
release of 7-amino-4-trifluoromethyl-coumarin (AFC) (Alexis) from DEVD containing 
synthetic peptides using continuous-reading plate reader (Wallac victor 2TM 
multilabel counter 1420) thermostated at 30°C at 400 /505 nm excitation and 
emission respectively. 
 
 
Table 7. Reagents for extraction of cytosolic fraction and caspase activation. 
HEB (20 mM PIPES, pH 7.0, 50 mM KCl, 2 mM MgCl2, 5 mM EGTA, 1 mM dithiothreitol) 
Caspase 
buffer 
(20 mM Pipes, 100 mM NaCl, 1 mM EDTA, 0.1% CHAPS, 10 % sucrose, 10 mM 
dithiothreitol) 
 
- Recombinant active caspase-8 and Smac protein were a gift from DR. Guy 
Salvesen La Jolla, USA. 
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Immunoprecipitation of caspase-3 
Equal amounts of cytosolic extracts were adjusted to a final volume of 500 µl with 
HEB. Samples were rotated for 6 h at 4 °C with 1 µg of anti-caspase-3 antibody. 
Antigen-antibody complexes were immobilized by rotation for 2 h at 4 °C with 
GammaBind G Sepharose (Pharmacia Biotech). The complexes were pelleted (1 
min, 14000 g) and the supernatant removed. After 3 cold washing steps with the 
same buffer used for the immunoprecipitation, samples were subjected to SDS-
PAGE and immunoblotted as described above. 
 
Table 8. Antibodies for immunoprecipitation. 
antigen description organism immunogene supplier Catalog No. 
hcaspase-3 Monoclonal Mouse aa 1-219 BD Transduction Lab. 610322 
 
Immunodepletion of XIAP. 
20 µl (250 µg/ml) of anti-XIAP Mab (transduction laboratories) were added to 100 µl 
of GammaBind G Sepharose (Pharmacia Biotech) in 500 µl of PBS and rotated at 
4°C for 3 h. The beads were collected by centrifugation (1 min  at 14000 g 4°C). After 
removal of the supernatant, the beads were washed once with 1 ml of HEB  and 
incubated with 300 µl of cytosolic extract (20 µg/µl) (KCl concentration was adjusted 
to 70 mM) for 6 h in a rotator at 4°C. The beads were subsequently pelleted by 
centrifugation (1 min.  at 14000 g 4°C). The resulting supernatant was the cytosolic 
extract immunodepleted of XIAP. 
 
Table 9. Antibodies for immunoprecipitation 
antigen description organism immunogene supplier Catalog No.
hILP/XIAP monoclonal/mouse aa 268.426 BD Transduction lab. 1/2500 H62120 
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Cloning and sequencing of XIAP and caspase-3 
Total RNA from 107 L1309, L1236, L591, L428 and KMH2 cells were isolated using 
RNeasy Mini Kit ( Qiagen). First-strand cDNAs were synthesized using SuperScript II 
for RT-PCR ( Gibco BRL). The cDNAs have been used for amplification of ORF 
(open reading frame) of XIAP and caspase-3 genes by using Pfu DNA polymerase ( 
Promega) . The primers used  were made by MWG-Biotech AG. 
 
Table 10. Primers used for PCR amplification of caspase-3 and XIAP. 
primers Sequence 5’-3’ 
XIAP-5’ 5’-ATG ACT TTT ACC AGT TTT GAA-3’ 
XIAP-3’ 5’-TTA AGA CAT AAA AAT TTT TTG-3’ 
Caspase-3-5’ 5’-ATG GAG AAC ACT GAA AAC TCA-3’ 
Caspase-3-3’ 5’-TTA GTG ATA AAA ATA GAG TTC-3’ 
 
The PCR products were clonned in PCR-2.1 vector (Invitrogene) and sequenced by 
using forward and reverse M13 primers. The complete procedure was done in 
duplicate and sequences were analyzed by Vector NTI program.    
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Results 
 
Induction of pro-apoptotic mitochondrial signaling by staurosporine 
Staurosporine has been described as a potent inducer of apoptosis through the 
mitochondrial pathway. Not only nontransformed cells, but also most tumor cells 
undergo apoptosis when treated with staurosporine (Stepczynska et al. 2001). The 
characteristic cascade of staurosporine-induced signaling is exemplified by HeLa 
cells as shown in Fig.6. As an immediate-early event, Bax activation/conformational 
change can be detected by a N-terminal epitope-specific antibody, 6A7, within 30 
min. of staurosporine treatment. The 6A7 monoclonal antibody recognizes Bax in a 
conformation with an exposed N-terminus, but not native Bax (Hsu et al. 1998, Hsu 
et al. 1997, Perez et al. 2000, Nechushtan et al. 1999 and Murphy et al. 2000). 
Immunoprecipitations were performed with cell lysates obtained by extraction with 
1% CHAPS. Consistent with published reports, lysis with CHAPS did not induce a 
Bax conformational change in untreated HeLa cells but Bax was in its native 
conformation and therefore was not immunoprecipitated by anti-Bax 6A7 antibody 
(Hsu et al. 1998, Hsu et al. 1997, Nechushtan et al. 1999 and Murphy et al. 2000). 
The N-terminal epitope of Bax became accessible for 6A7 binding after treatment of 
HeLa cells with staurosporine. Notably, the total amount of Bax protein remained 
unchanged, indicating that the increasing fraction of active Bax protein does not 
correspond to newly synthesized protein. Concomitantly, cytochrome c was released 
from mitochondria into the cytosol. Activation of caspase-3 occurred with slightly 
delayed kinetics, indicated by the processing into the p20/p17 fragments. These 
results are in line with the previously proposed sequence of events in mitochondrial 
apoptosis, where cytochrome c release is induced by the activation of Bax, which 
eventually results in the activation of caspase-3 as an executioner caspase. 
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Fig. 6: Bax activation, cytochrome c release and caspase activation in HeLa cells. Cells were 
treated for 5 h with 1 µM staurosporine, aliquots of cell lysates were prepared at the timepoints 
indicated. Total cell extracts and cytosolic extracts were subjected to SDS-PAGE and western blotting. 
Activated Bax was immunoprecipitated in the whole cell extracts with the conformation specific 
antibody 6A7 and subsequently detected by human Bax antiserum and compared to the total amount 
of Bax in the lysates. Cytochrome c and caspase-3 were detected in cytosolic extracts. Reprobing for 
Actin ensured equal loading. 
 
Staurosporine resistance of Hodgkin derived B cell lines 
Previously published reports have shown that most tumor cell lines investigated 
proved sensitive to staurosporine (Stepczynska et al. 2001). However, when HD B 
cells were investigated, L428, L591, L1236 and KMH2 showed a marked resistance 
to staurosporine in comparison to control cell lines (Fig. 7). In the first attempt, the 
expression of proteins involved in the mitochondrial apoptosis pathway was 
examined by western blot analysis (Fig. 8). Bcl-XL, one of the major anti-apoptotic 
proteins, was expressed in all HD B cell lines tested. In contrast, another anti-
apoptotic protein, Bcl-2, was expressed at lower levels in HD B-cell lines compared 
to control B-cells. The expression of Bax and caspase-3 was comparable in all cell 
lines, whereas the Hodgkin B cells contained slightly less Bak protein compared to 
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the control cells. Taken together, HD B cells did not reveal an uniform expression 
pattern of pro- or anti-apoptotic proteins that would explain the staurosporine-
resistant  phenotype.  
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Fig. 7: Induction of cell death by
staurosporine. Cells were treated
for 0-24 h with 1 µM staurosporine.
Cell death was determined by
trypanblue exclusion. Each time
point represents the average of
duplicate experimental values. The
figure represents one
representative experiment out of
three. 
Fig. 8: Expression of pro- and
antiapoptotic proteins in Hodgkin
cell lines. Equal amounts of total
cell lysates from the cells indicated
were subjected to SDS-PAGE and
western blotting. Proteins were
detected after incubation with
antibody specific for Bcl-2, Bcl-XL,
Bax, Bak, or Caspase-3 followed by
secondary antibody and ECL as
described in material and methods.
Equal loading was confirmed by
detection of Actin on the same
membranes. 
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Defective Bax-activation in HD  B cell lines 
The mere presence or absence of members of the apoptotic pathway does not allow 
conclusions with respect to intact or defective mitochondrial signaling. This is 
because rather complex interactions of the proteins of the Bcl-2 family and caspases 
involving homo- and heterodimerization, conformational changes, and post-
translational processing, seem to regulate the mitochondria-associated apoptosis.To 
test for putative defects in the mitochondrial apoptotic pathway, HD B cell lines were 
therefore scrutinized for the characteristic sequence of events shown in Fig. 6. As 
shown in Fig. 9, staurosporine-treated L591, L1236, L428 and KMH2 cells do neither 
show activation of Bax, nor cytochrome c release from the mitochondria or 
processing of caspase-3. In contrast, an intact mitochondrial signaling including Bax 
conformational change, cytochrome c release and caspase-3 processing was 
observed in L1309, L1311, LCL6 and C28 cells, EBV transformed non-malignant B 
cell lines used as control. 
To confirm the lack of Bax activation in the HD B-cells, immunofluorescence staining 
of Bax with anti-Bax 6A7 antibody, recognizing activated Bax protein, were 
performed. Fig. 10 shows the Bax staining (red) merged with nuclei staining (blue). 
Consistent with our immunoprecipitation results, untreated L1309, L591 and KMH2 
cells were negative for staining with 6A7. Treatment of L1309 cells with staurosporine 
induced a conformational change in Bax, resulting in a punctuated staining pattern 
(Murphy et al. 2000) as early as 2 h of treatment, while nuclear fragmentation was 
observed at later time points in a significant proportion of cells. Neither Bax staining 
nor nuclear fragmentation was observed in L591 and KMH2 cells after staurosporine 
treatment up to 12 h, indicating a lack of activated Bax protein and apoptosis. 
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Fig. 9: Bax activation, cytochrome c release and caspase activation in Hodgkin and control cell 
lines. Cells were treated for 6 h with 1 µM staurosporine, aliquots of cell lysates were prepared at the 
timepoints indicated. Total cell extracts and cytosolic extracts were subjected to SDS-PAGE and 
western blotting. Activated Bax was immunoprecipitated in the whole cell extracts with the 
conformation specific antibody 6A7 and subsequently detected by human Bax antiserum and 
compared to the total amount of Bax in the lysates. Cytochrome c and Caspase-3 were detected in 
cytosolic extracts. Reprobing for Actin ensured equal loading. 
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Fig. 10: Bax activation by staurosporine-treatment. L1309, L591 and KMH2 cells were treated for 
0, 2, 4, 6 and 12 h with 1 µM staurosporine, and immunostained using 6A7 antibody detecting 
exposure of the Bax N-terminus. Bax N-terminus staining is seen as red fluorescence, while nuclei are 
stained blue after counterstaining with Hoechst 33258.   
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Lack of caspase-3 activity in HD B cells 
Induction of apoptosis and activation of the caspase cascade leads to processing 
and enzymatic activity of the executioner caspase, caspase-3, at the distal end of this 
cascade. The caspase-3 antibody stained some low molecular weight proteins in the 
cytosolic extracts of L428, L591 and KMH2 cells. These bands do not represent the 
right size of properly processed caspase-3 and do not suggest enzymatic activity of 
caspase-3. To rule out the remote possibility of aberrant caspase activation, the 
activity of caspase-3 was measured by an independent assay system. Caspase 
activity of cytosolic extracts from L591, L1236, L428, KMH2, L1309, L1311, LCL6, 
and C28 control cells treated with staurosporine for the times indicated, was 
measured using the fluorogenic substrate DEVD-AFC. As shown in Fig.11, 
staurosporine-induced caspase activity was only observed in L1309, L1311, LCL6 
and C28 control B cells with a maximum at 6 hours of treatment. No significant 
activation of caspases could be measured in staurosporine treated L591, L1236, 
L428 and KMH2 cells, confirming the results obtained by western blot analysis. 
The possibility of delayed cytochrome c release and caspase-3 processing in HD B 
cells compared to the control B cell line L1309 was ruled out by extended kinetic 
analysis of cytosolic cytochrome c and caspase-3 processing by western blotting in  
parallel to measurements of caspase-3 activation using the fluorogenic substrate 
DEVD-AFC (Fig. 12). In the control cell line L1309 the peak activity of caspase-3 was 
observed 6 hours after induction of apoptosis with staurosporine, decreasing 
thereafter due to cell death and degradation of the apoptotic cell fragments. Western 
blotting for proteolytic cleavage during the activation of caspase-3 confirmed the 
peak of caspase-3 activity at 6 hours of staurosporine treatment. In the staurosporine 
resistant cell lines, neither cytochrome c release nor proteolytic cleavage and 
subsequent activity of caspase-3 could be detected within 24 hours of treatment with 
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staurosporine, indicating that cytochrome c release and caspase-3 activation do not 
occur at all. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11: Staurosporine-induced caspase activity. Cells were treated with 1 µM staurosporine. 
Cytosolic extracts were prepared after 0, 3, 6, 12, 24, and 48 h of treatment. Caspase activity was 
measured by hydrolysis of DEVD-afc. Samples were normalized for total cytosolic protein content. 
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Fig. 12: Staurosporine-induced caspase processing and activity. L1236, KMH2, and L1309 
control cells were treated with 1 µM staurosporine. Cytosolic extracts were prepared after 0, 3, 6, 12 
and 24 h of treatment. Caspase activity was measured by hydrolysis of DEVD-afc. Samples were 
normalized for total cytosolic protein content. Cytosolic extracts were also subjected to SDS-PAGE 
and western blotting. Cytochrome c and Caspase-3 were detected in cytosolic extracts. 
 
 
Failure of processing and activation of caspase-9 and -3 in HD B cells  
So far, the data provided showed that HD B cell lines have a defect in the 
mitochondrial apoptotic pathway upstream of mitochondria, which contributes to 
resistance to apoptosis induction by staurosporine. In order to investigate if caspases 
are functional in these cells, a cell-free system based on the ability of exogenously 
added cytochrome c to induce proteolytic processing of procaspase-9 and -3 was 
employed (Liu et al. 1996, and Deveraux et al. 1998). First, the sequential activation 
of caspase-9 and caspase-3 after addition of cytochrome c to cytosolic extracts was 
analyzed. The four HD B cell lines, L1236, L591, L428, KMH2, and the control B cell 
line L1309 were subjected to this analysis. As shown in Fig. 13A, in untreated cell 
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extracts caspase-9 is detected as its 46-kDa proform. Addition of cytochrome c to the 
cytosolic extracts of L1309 leads to autocatalytical cleavage of procaspase-9, 
producing the characteristic p35 fragment of caspase-9. A second cleavage, 
mediated by subsequently activated caspase-3, results in the p37 fragment of 
caspase-9 (Srinivasula et al. 1998). Concomitantly, the initial p20 and ultimate p17 
fragments of caspase-3 were detected (Fig. 13B). In contrast to the control B cell 
line, cytochrome c failed to induce any processing of caspase-9 in cytosolic extracts 
of HD B cell lines. Similarly, caspase-3 remained in its inactive form after addition of 
cytochrome c to the cytosolic extracts of all HD B cell lines (Fig. 13A, B). Addition of 
cytochrome c to cytosolic extracts induced caspase-3 enzymatic activity in the control 
B cell line but not in the HD B cell lines which corresponds to the defective 
processing of both, caspase-9 and caspase–3 (Fig. 13C).  
The defective caspase activation in the HD B cell lines prompted us to examine the 
expression of proteins involved in this process downstream of mitochondria. As 
shown in Fig. 14A and B,  Apaf-1, cytochrome c and Smac/DIABLO are expressed in 
all cell lines at comparable levels. Notably, the lack of detection of cytochrome c and 
Smac in the cytosolic fractions excluded that a possible contamination of cytosolic 
fractions by mitochondrial proteins would have caused caspase activation in the 
control B cell line. In contrast, the anti-apoptotic protein XIAP appeared to be 
significantly overexpressed in the HD B cell lines L1236, L591, L428, and KMH2, 
compared to the control B cell line L1309.   
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Fig.13. Failure of cytochrome c to induce caspase activation in cytosolic extracts of HD B cell 
lines. Cytosolic extracts of L1309, L1236, L591, L428, and KMH2 cells were prepared and equal 
amounts of protein were incubated with or without cytochrome c/dATP for 1h at 30°C. Cytosolic 
extracts were resolved by SDS/PAGE and subjected to western blot analysis. A) Procaspase-9 (p46) 
and the processed fragments (p37, p35) were detected by polyclonal rabbit anti-caspase-9 antibody. 
B) Procaspase-3 (p32) and the processed fragments (p20, p17) were detected by polyclonal anti-
caspase-3 antibody. C) Measurement of relative caspase-3 activity was performed, using DEVD-AFC. 
Samples were normalized for total cytosolic protein content. Asterisks (∗) indicate nonspecific bands 
recognized by polyclonal antibodies. 
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XIAP association with caspase-3 in HD B cell lines   
XIAP inhibits the catalytic activity of caspases through physical interaction (Deveraux 
et al. 1998, and Srinivasula et al. 2001). The observation that XIAP is abundantly 
expressed in HD B cell lines prompted us to examine whether XIAP is associated 
with caspase-3 in these cell lines. As shown in Fig. 15A, XIAP was detected in 
cytosolic extracts of control and HD B cell lines at about 54 kDa. Addition of 
cytochrome c appeared to induce partial degradation of XIAP in the control and in HD 
B cell cytosolic extracts into one detectable fragment at about 48 kDa. 
Immunoprecipitation of caspase-3 co-precipitated large amounts of XIAP in cysolic 
extracts of HD B cell lines but not in that of the control B cell line. That indicates a 
physical interaction of XIAP with caspase-3, a hallmark for the aberrant antiapoptotic 
function of XIAP in HD B cells (Fig. 15B).  
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Fig. 14. Expression of caspase
activators and inhibitors in HD B cell
lines. Equal amounts of proteins from
total cell lysate, cytosolic and membrane
fractions (including mitochondria) of
L1309, L1236, L591, L428, and KMH2
cells were subjected to SDS/PAGE and
western blot analysis. Proteins were
detected by antibodies against Apaf-1,
XIAP, Smac, and Cytochrome c, followed
by secondary antibody and ECL as
described in material and methods. 
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Fig.15. XIAP co-immunoprecipitates with caspase-3 in immunoprecipitation analysis. Cytosolic 
extracts of L1309, L1236, L591, L428, and KMH2 cells were prepared and equal amounts of protein 
were incubated with or without cytochrome c/dATP for 1h at 30°C. A) Samples were resolved by 
SDS/PAGE and subjected to western blot analysis. XIAP was detected by mouse anti-XIAP antibody. 
B) Caspase-3 was immunoprecipitated by mouse anti-caspase-3 antibody in cytosolic extracts and 
subjected to SDS/PAGE and western blotting. Co-precipitated XIAP was detected by mouse anti-XIAP 
antibody. The asterisk (∗) indicates  Mouse IgG.  
   
Caspase-8 and granzyme B partially bypass the XIAP-mediated inhibition of 
caspase-3 in HD B cell lines.  
XIAP is known to suppress apoptosis induced by stimulation of both, death receptor 
and mitochondrial pathways (Deveraux et al. 1998, and Deveraux et al. 1997). To 
detect the target of XIAP action, caspase-3 was activated by the other initiator 
proteases caspase-8 or granzyme B (Martin et al. 1996 and Muzio et al. 1997). 
Indeed, when recombinant active caspase-8 or granzyme B were added to the 
cytosolic extracts of HD B cells, these two proteases stimulated the cleavage of 
caspase-3 resulting in the p20 fragment, characteristic of the initial cleavage of 
caspase-3 (Martin et al. 1996, Deveraux et al. 1998 and Deveraux et al. 1997) (Fig. 
16A and 17A). Notably, the autocatalytic maturation generating the p17 fragment, 
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proceeds to a lesser degree in the cytosolic extracts of HD B cell lines compared to 
the control B cell line. We conclude that in HD B cells XIAP does not prevent the 
initial cleavage of caspase-3 induced by caspase-8 or granzyme B, but rather inhibits 
the subsequent autocatalytic processing to the mature p17 fragment. As shown in 
Fig. 16B and 17B, incomplete caspase-3 processing corresponds with decreased 
caspase-3 activity in HD B cell extracts.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.16. Caspase-3 activation by caspase-8. Cytosolic extracts of L1309, L1236, L591, L428, and 
KMH2 cells were prepared and equal amounts of protein were left untreated or incubated for 1h with 
recombinant active caspase-8 at 30°C. A) Cytosolic extracts were resolved by SDS/PAGE and 
subjected to western blot analysis. Caspase-3 was detected by polyclonal rabbit anti-caspase-3 
antibody. B) Relative caspase-3 activity was measured, using DEVD-AFC after incubation with 
recombinant active caspase-8. Samples were normalized for total cytosolic protein content. 
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Fig.17. Caspase-3 activation by granzyme B. Cytosolic extracts of L1309, L1236, L591, L428, and 
KMH2 cells were prepared and equal amounts of protein were left untreated or incubated for 1h with 
recombinant granzyme B at 30°C. A) Cytosolic extracts were resolved by SDS/PAGE and subjected to 
western blot analysis. Caspase-3 was detected by polyclonal rabbit anti-caspase-3 antibody. B) 
Relative caspase-3 activity was measured, using DEVD-AFC after incubation with recombinant active 
granzyme B. Samples were normalized for total cytosolic protein content. 
 
The observation that caspase-8 overcomes caspase-3 inhibition by XIAP to a greater 
extent than does granzyme B, might be explained partly by its ability to cleave XIAP 
into different fragments, which results in the depletion of the full length XIAP (Fig. 
18A, B) and is accompanied by the loss of its inhibitory activity (Deveraux et al. 1999-
a).  
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Taken together, the data in Fig. 16 and 17 suggest that caspase-3 in HD B cells can 
be processed by addition of initiator proteases like caspase-8 and granzyme B, but 
that its activity is checked by XIAP. The competence of caspase-3 in HD B cell lines 
was confirmed by sequence analyses of caspase-3, that revealed a lack of mutations 
in this gene (appendix).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig.18. Degradation of XIAP by caspase-8. Cytosolic extracts of L1309, L1236, L591, L428 and 
KMH2 cells were prepared and equal amounts of proteins were left untreated or incubated for 1h at 
30°C with A) recombinant active caspase-8 or B) Granzyme B. Cytosolic extracts were resolved by 
SDS/PAGE and subjected to western blot analysis. XIAP (p54) and XIAP fragments (p48, p30/34, 
p25) were detected by mouse anti-XIAP antibody. 
 
Physical or functional depletion of XIAP restores cytochrome c induced caspase-3 
activity in HD B cells. 
So far our data show that in HD B cell lines XIAP is overexpressed, inhibits the initial 
cleavage of caspase-3 mediated by the caspase-9 in the apoptosome and prevents 
caspase-3 activation. Moreover, XIAP may also act at the level of caspase-3 to shut 
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down the caspase-8 mediated death receptor pathway and the granzyme B pathway. 
If XIAP was the key inhibitor of apoptosis in HD B cells, removal of XIAP should 
relieve the inhibition of caspase-3 activation. To provide further evidence for the 
effect of XIAP on the mitochondrial apoptotic pathway in HD B cells, XIAP was 
removed from cytosolic extracts by two independent methods. First, a mitochondrial 
inhibitor of XIAP, Smac, was added to cytosolic extracts, pretreated with cytochrome 
c. As shown in Fig. 19A recombinant Smac protein restores the ability of cytochrome 
c to trigger processing and activation of caspase-3 in HD B cells. Corresponding to 
the processing of caspase-3 into the p20 and the ultimate p17 fragments, addition of 
Smac to cytosolic extracts of HD B cell lines restored the enzymatic activity of 
caspase-3 (Fig. 19B). As a second approach, XIAP was immunodepleted from 
cytosolic extracts of KMH2 cells, using a mouse monoclonal anti-XIAP antibody. As 
shown in Fig. 19C, immunodepletion of XIAP resulted in an enhancement of 
caspase-3 activity, providing further evidence for a central role of XIAP in inhibition of 
caspase-3 activation in HD B cells. 
To distinguish whether activation or proteolytic activity of caspase-3 is inhibited in HD 
B cells, we pre-incubated active mature caspase-3 in cytosolic extracts of HD and 
control B cell lines and subsequently measured the DEVDase activity of caspase-3. 
As shown in Fig. 20, the activity of exogenously added mature caspase-3 in cytosolic 
extracts of HD B cell lines was not inhibited, indicating that it is the caspase-3 
activation pathway which is blocked in HD B cell lines.  
 
 
 
 
 
 
  Results 
 43
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.19. Depletion of XIAP restores caspase-3 processing and activity. Cytosolic extracts of 
L1309, L1236, and KMH2 cells were prepared and equal amounts of protein were incubated with or 
without cytochrome c/dATP in the absence and presence of Smac protein for 1h at 30°C. A) Cytosolic 
extracts were resolved by SDS/PAGE and subjected to western blot analysis. Caspase-3 was 
detected by polyclonal rabbit anti-caspase-3 antibody. B) Relative caspase-3 activity was measured 
by hydrolysis of DEVD-AFC. Samples were normalized for total cytosolic protein content. C) XIAP was 
immunodepleted by mouse anti-XIAP antibody. Cytosolic extracts of KMH2 cells with or without XIAP 
were incubated in the presence or absence of cytochrome c/dATP for 1h at 30°C. Samples were 
normalized for total cytosolic protein content and relative caspase-3 activity was measured by 
DEVDase activity. 
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Fig.20. Mature caspase-3 is not inhibited in cytosolic extracts of HD B cell lines. Cytosolic 
extracts of L1309, L1236, L591, L428 and KMH2 cells were prepared and equal amounts of protein 
were pre-incubated with or without exogenously added mature caspase-3. Samples were normalized 
for total cytosolic protein content and relative caspase-3 activity was measured by DEVDase activity. 
 
As shown in Fig. 21, addition of Smac protein to cytosolic extracts of L1236 and 
KMH2 cells also promoted caspase-9 processing into p35 and p37 fragments. The 
additional inhibition of XIAP by Smac also restored the processing of caspase-9, 
suggesting that XIAP not only prevents maturation of caspase-3 but more likely 
inhibits the caspase-9 mediated initial cleavage of caspase-3 by inhibiting caspase-9 
activation. 
 
 
 
 
 
Fig.21. Smac restores caspase-9 processing in HD B cell line. Cytosolic extracts of L1309, L1236, 
and KMH2 cells were prepared and equal amounts of proteins were left untreated or incubated for 1h 
at 30°C with cytochrome c/dATP in the presence or absence of Smac protein. Cytosolic extracts were 
resolved by SDS/PAGE and subjected to western blot analysis. Caspase-9 was detected by polyclonal 
rabbit anti-caspase-3 antibody. 
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Discussion 
 
Four neoplastic B cell lines established from patients with Hodgkin's disease were 
shown to be resistant to staurosporine induced cell death. The results of this study 
revealed that these HD B cell lines have developed a resistance to apoptosis by 
alteration of the mitochondrial signaling pathway, which manifests in the failure to 
trigger the release of cytochrome c from mitochondria and subsequent caspase 
activation. By detailed analysis of the mitochondrial apoptosis pathway, one signaling 
defect was localized upstream of mitochondria at the level of Bax activation. A further 
defect in apoptotic signaling has been identified and localized in the caspase 
cascade downstream of mitochondria. The data provided by using a cell-free system 
indicate that the cytochrome c induced activation of caspase-9 and –3 is severely 
impaired in HD B cell lines. The evidence provided suggests that XIAP is 
overexpressed in HD B cells, constitutively binds to caspase-3, and plays a key role 
in the inhibition of caspase-3 processing and activation. 
Hodgkin's disease is a lymphoid neoplasm characterized by low-frequent malignant 
tumor giant cells, known as H-RS cells, in a microenvironment of abundant non-
neoplastic inflammatory cells. The HD cell lines used in this study, L428, L591, 
L1236, and KMH2, are well characterized with regard to their morphology and 
immunophenotype and display typical B cell associated markers (Drexler 1993 and 
Mauch et al. 1999). For example, immunoglobulin rearrangements were detected in 
L1236 cells, proving that this cell line is of clonal B cell origin (Kanzler et al. 1996). 
Like primary H-RS cells, Hodgkin derived B cell lines have been shown to be 
resistant to apoptotic stimuli like CD95 (Re et al. 2000). The PKC-inhibitor 
staurosporine is a classical inducer of the mitochondrial apoptotic pathway in a broad 
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spectrum of nontransformed and tumor cells. All HD B cells were resistant to cell 
death induction by staurosporine and showed a defect in Bax activation, whereas 
their nonmalignant B cell counterparts displayed an intact mitochondrial apoptosis 
pathway. In the HD B cell lines Bax activation could be disturbed by a variety of 
possible mechanisms. The pro-apoptotic protein Bax can not only form homodimers 
but has also been shown to interact with a variety of other proteins (Murphy et al. 
2000, Korsmeyer 1995, and Martinou 1999). For example, Bax could be bound to 
anti-apoptotic Bcl-2 family members or to presently unknown proteins, masking Bax 
and preventing its activation. Overexpression of Bcl-2 and Bcl-XL, for example, can 
inhibit Bax function and cytochrome c release from mitochondria, which subsequently 
leads to a failure to activate the executioner caspases.  
Like HD B cell lines, most HD biopsies however, stained positive for Bax and/or Bak 
(Reed et al.  1996, Brousset et al. 1996, Schlaifer et al. 1997, Chu et al. 1999, and 
Kanavaros et al. 2000). This leads to the conclusion that the cell death promoting 
activity of Bax might be neutralized by other apoptosis regulating proteins (Brousset 
et al. 1996). In many tumors, resistance to apoptosis was shown to be secondary to 
high levels of anti-apoptotic Bcl-2 like proteins and/or low level expression of their 
pro-apoptotic counterparts.  Besides Bcl-2, HD B cells expressed Bcl-XL, another 
anti-apoptotic member of the Bcl-2 family. Bcl-XL expression has been previously 
observed by immunohistochemical analysis of HD biopsies.  However, Bcl-XL is also 
expressed by nonmalignat B cells. Furthermore, Bcl-XL has not been shown to be a 
target for staurosporine. HD B cells provide the first example for a tumor entity, 
where resistance to mitochondrial apoptosis seems to be brought about by a 
regulatory defect controlling Bax activation. Clearly, the molecular mode of 
staurosporine action and, in particular, its failure in HD B cells has yet to be 
elucidated. 
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Apoptosis pathways consist of a cascade of signaling proteins before the final 
irreversible decision to die is made. The whole pathway is tightly regulated not only 
by the members of the Bcl-2 family, but also by the inhibitors of apoptosis (IAPs), and 
the Smac/DIABLO proteins. Therefore, resistance to apoptosis can be acquired by 
regulation of different steps in the pathway.  
In the cytosolic extracts of HD B cell lines cytochrome c/dATP addition failed to 
activate caspase-9 and –3. Correspondingly, neither the initial cleavage of caspase-9 
through autocatalysis nor any subsequent proteolytic cleavage mediated by caspase-
3 was observed. When complexed with Apaf-1 and cytochrome c, caspase-9 is 
cleaved and converted into an active protease. Activated caspase-9 then cleaves 
and activates caspase-3 (Li et al. 1997). 
It is important to note that Apaf-1, caspase-9 and –3 were expressed at the same 
levels (Fig.13, 14) and caspase-3 did not reveal any mutations in the primary 
structure. From these data can be inferred that one of the caspase inhibitors might 
prevent caspase processing and activation in HD B cells. Indeed, XIAP was found to 
be overexpressed in all HD B cells (Fig. 14A). XIAP is the most potent caspase 
inhibitor of all known IAPs, which suppress apoptosis induced by different stimuli 
(Deveraux et al. 1998 and Deveraux et al. 1997). XIAP inhibits the catalytic activity of 
caspases by physically interacting with them. The finding that XIAP could be co-
immunoprecipitated with caspase-3 in HD B cells but not in control B cells, supported 
the hypothesis that XIAP binds constitutively to caspase-3. That the binding of XIAP 
to caspase-3 results in inhibition of this protease was demonstrated by functional and 
physical removal of XIAP from cytosolic extracts.  
Addition of recombinant Smac protein, an IAP inhibitor that is able to displace 
caspases from the complex with XIAP, restores the activation of caspase–3 induced 
  Discussion 
 48
by cytochrome c/dATP. Caspase-3 activation was also restored when XIAP was 
immunodepleted from cytosolic extracts of the HD B cell lines. 
In conclusion, four lines of evidence suggest that XIAP inhibits caspase-3 in HD B 
cell lines i) XIAP is overexpressed, ii) XIAP co-immunoprecipitates with caspase-3, iii) 
the XIAP inhibitor Smac restores caspase-3 activity, and iv) physical removal of XIAP 
by immunodepletion promotes caspase-3 activation.  
As an executioner caspase, caspase-3 represents a target of converging caspase 
cascades including caspase-8, caspase-9 and granzyme B. When added to cytosolic 
extracts of HD B cells, caspase-8 and granzyme B induced protease activity of 
caspase-3, although at reduced levels. This is due to the initial cleavage into large 
and small subunits, while autocatalytic processing is still inhibited by XIAP (Martin et 
al. 1996, Deveraux et al. 1998 and Deveraux et al. 1997). In contrast to caspase-8 
and granzyme B, cytochrome c/dATP induced caspase-3 activation was completely 
abrogated. This is explained by the observation that XIAP inhibits activation of 
caspase-9. Thus the inhibitory activity of XIAP is not restricted to caspase-3, but 
rather involves the level of the apoptosom. Upon addition of cytochrome c/dATP, 
Apaf-1 forms oligomers which recruit caspase-9 and caspase-3 sequentially. 
Interestingly, XIAP appears to be recruited to the apoptosom through a caspase-9 
and -3 independent but dATP dependent binding to Apaf-1. In the Apoptosome XIAP 
simultaneously binds to and inhibits both, caspase-9 and caspase-3 activation 
(Bratton et al. 2001). 
Overexpression of XIAP has been shown to effectively inhibit a variety of cell death 
programs (Deveraux et al. 1999-b). These observations suggest that XIAP may play 
a key role in the regulation of apoptosis in cancer cells, as also shown in melanoma 
(Zhang et al. 2001). The XIAP gene obviously can be upregulated by NF-κB (Stehlik 
et al. 1998 and Lee et al. 2001). Interestingly, H-RS cells strongly express CD30 and 
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CD40, two members of  the TNF receptor family that both can activate NF-κB. 
Constitutive activation of NF-κB appears to be an unique feature of H-RS cells, which 
is suggested to play an important role in the pathogenesis of H-RS cells (Bargou et 
al. 1997, Hinz et al. 2001, Izban et al. 2001 and Fiumara et al. 2001). The 
overexpression of XIAP as a target gene for NF-κB is in line with these observations 
and provides a plausible link for NF-κB mediated resistance to apoptosis in HD B 
cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.22. XIAP mediated inhibition of apoptosis in HD B cell lines. Upstream of mitochondria, XIAP 
prevents activation of Bax possibly through phosphorylation and activation of Akt (1). Since activated 
Bax is a potent trigger of cytochrome c release, the inhibition of Bax activation impairs the release of 
proapoptotic factors from mitochondria. Through binding to caspase-9 in the apoptosome XIAP 
prevents the conversion of caspase-9 into the active protease and thereby blocks the initial cleavage 
of caspase-3 (2). Finally, XIAP directly binds to caspase-3 and blocks the autocatalytic maturation of 
caspase-3 (3).   
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Recent reports indicate that XIAP can prevent apoptosis through a PI3/Akt 
(phosphoinositide 3-OH kinase /protein-serine/threonine kinase) dependent inhibition 
of the caspase cascade. Apparently, XIAP can stimulate Akt phosphorylation and 
activation (Asselin et al. 2001). Akt/PI3 Kinases in turn have been reported to 
regulate apoptotic events by modulating the function of Bcl-2 family members (Deng 
et al. 2000, Yamaguchi et al. 2001 and Ito et al. 1997). Specially, Bax conformational 
change can be inhibited by Akt activation (Yamaguchi et al. 2001). Thus, 
overexpression of XIAP would be one possible explanation for the lack of Bax 
activation in HD B cells. These observations can be reconciled in a model, where 
overexpressed XIAP exerts its anti-apoptotic effects at three levels of the 
mitochondrial apoptotic pathway as shown in Fig. 22. Overexpressed XIAP in HD B 
cells might inhibit the activation of Bax by enhancing phosphorylation of Akt and 
thereby blocks the efflux of cytochrome c and probably Smac/DIABLO into the 
cytosol. The attraction of XIAP to the apoptosome after addition of  cytochrome c 
results in spatial proximity of XIAP to both, caspase-9 and caspase-3, where it fulfills 
its dual caspase inhibitory function by simultaneously binding to these two caspases 
via distinct separate motives.   
Certain classes of signaling proteins and pathways are targeted frequently by 
oncogenic mutations resulting in cancer (Blume-Jensen et al. 2001). The PI3 Kinase 
and some of its downstream targets, such as the Akt, are crucial effectors in 
oncogenic kinase signaling. Protein kinases are important regulators of intracellular 
signal-transduction pathways mediating development and multicellular 
communication. Their activity is normally tightly controlled and regulated. 
Deregulated kinase activity has been shown to inhibit apoptosis and lead to 
malignant transformation (Franke et al 1997). Recent reports suggest that 
phosphorylation of Bcl-2 enhances its anti-apoptotic activity and inhibits the release 
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of cytochrome c from mitochondria. The phosphorylation of Bcl-2 occurs to be a 
result of different kinase activities including those of the IL-3 activated MAP-kinase 
pathway. Furthermore, staurosporine can only partially inhibit IL-3 stimulated Bcl-2 
phosphorylation, suggesting the existence of IL-3 activated, staurosporine resistant 
kinases (SRKs) in the cells (Deng et al. 2000). Interestingly, recent report suggested 
that over 90% of H-RS cells in tissues and all tested HD B cell lines strongly 
expressed the IL-3 receptor, which could serve as a kinase activator in these cells 
(Aldinucci et al. 2002). The resistance to staurosporine, the blocked Bax activity and 
the overexpression of both, the IL-3 receptor and XIAP in HD B cell lines provide 
several lines of evidence that suggest an Akt or Akt-like hyperactivity in HD B cell 
lines. Further investigation of protein kinase pathways in these cells with the 
emphasis on the evaluation of possible linkages to apoptotic pathways will raise new 
opportunities to understand the mode of resistance to apoptosis in HD B cell lines.   
Survival of cancer cells requires the continuous input of survival signals to suppress 
apoptosis. The mitochondrial apoptotic pathway is thought to be the principal target 
of survival signaling pathways, which act by stabilizing mitochondrial function and 
integrity and suppressing the release of cytochrome c. A particularly potent driving 
force for the suppression of apoptosis in tumor cells is the deregulation of the 
mitochondrial apoptotic pathway, a phenomenon exemplified by overexpression of 
members of the anti-apoptotic Bcl-2 protein family, overexpression of IAPs or loss of 
Apaf-1 in several tumor types (Deng et al. 2002, Soengas et al. 2001 and Evan et al. 
2001). Understanding the functions and molecular interactions in the mitochondrial 
apoptotic pathway is the key to the breadth of therapeutic opportunities. Apoptosis-
modulating therapeutics, which are mostly converged at the mitochondrial site of 
apoptotic pathways, are now in human clinical trials or are on the brink, having 
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shown efficacy in preclinical animal models. Thus apoptosis research may propel 
significant progress in cancer therapy. 
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Appendix 
 
 XIAP Alignment 
Section 1 
ATGACTTTTAACAGTTTTGAAGGATCTAAAACTTGTGTACCTGCAGACATCAAT L1309 (1) 
ATGACTTTTAACAGTTTTGAAGGATCTAAAACTTGTGTACCTGCAGACATCAAT L1236 (1) 
ATGACTTTTAACAGTTTTGAAGGATCTAAAACTTGTGTACCTGCAGACATCAAT L591 (1) 
ATGACTTTTAACAGTTTTGAAGGATCTAAAACTTGTGTACCTGCAGACATCAAT L428 (1) 
ATGACTTTTAACAGTTTTGAAGGATCTAAAACTTGTGTACCTGCAGACATCAAT KMH2 (1) 
ATGACTTTTAACAGTTTTGAAGGATCTAAAACTTGTGTACCTGCAGACATCAAT 7159760 (1) 
ATGACTTTTAACAGTTTTGAAGGATCTAAAACTTGTGTACCTGCAGACATCAAT Consensus (1) 
 
Section 2 
AAGGAAGAAGAATTTGTAGAAGAGTTTAATAGATTAAAAACTTTTGCTAATTTT L1309 (55) 
AAGGAAGAAGAATTTGTAGAAGAGTTTAATAGATTAAAAACTTTTGCTAATTTT L1236 (55) 
AAGGAAGAAGAATTTGTAGAAGAGTTTAATAGATTAAAAACTTTTGCTAATTTT L591 (55) 
AAGGAAGAAGAATTTGTAGAAGAGTTTAATAGATTAAAAACTTTTGCTAATTTT L428 (55) 
AAGGAAGAAGAATTTGTAGAAGAGTTTAATAGATTAAAAACTTTTGCTAATTTT KMH2 (55) 
AAGGAAGAAGAATTTGTAGAAGAGTTTAATAGATTAAAAACTTTTGCTAATTTT 7159760 (55) 
AAGGAAGAAGAATTTGTAGAAGAGTTTAATAGATTAAAAACTTTTGCTAATTTT Consensus (55) 
 
Section 3 
CCAAGTGGTAGTCCTGTTTCAGCATCAACACTGGCACGAGCAGGGTTTCTTTAT L1309 (109) 
CCAAGTGGTAGTCCTGTTTCAGCATCAACACTGGCACGAGCAGGGTTTCTTTAT L1236 (109) 
CCAAGTGGTAGTCCTGTTTCAGCATCAACACTGGCACGAGCAGGGTTTCTTTAT L591 (109) 
CCAAGTGGTAGTCCTGTTTCAGCATCAACACTGGCACGAGCAGGGTTTCTTTAT L428 (109) 
CCAAGTGGTAGTCCTGTTTCAGCATCAACACTGGCACGAGCAGGGTTTCTTTAT KMH2 (109) 
CCAAGTGGTAGTCCTGTTTCAGCATCAACACTGGCACGAGCAGGGTTTCTTTAT 7159760 (109) 
CCAAGTGGTAGTCCTGTTTCAGCATCAACACTGGCACGAGCAGGGTTTCTTTAT Consensus (109) 
 
Section 4 
ACTGGTGAAGGAGATACCGTGCGGTGCTTTAGTTGTCATGCAGCTGTAGATAGA L1309 (163) 
ACTGGTGAAGGAGATACCGTGCGGTGCTTTAGTTGTCATGCAGCTGTAGATAGA L1236 (163) 
ACTGGTGAAGGAGATACCGTGCGGTGCTTTAGTTGTCATGCAGCTGTAGATAGA L591 (163) 
ACTGGTGAAGGAGATACCGTGCGGTGCTTTAGTTGTCATGCAGCTGTAGATAGA L428 (163) 
ACTGGTGAAGGAGATACCGTGCGGTGCTTTAGTTGTCATGCAGCTGTAGATAGA KMH2 (163) 
ACTGGTGAAGGAGATACCGTGCGGTGCTTTAGTTGTCATGCAGCTGTAGATAGA 7159760 (163) 
ACTGGTGAAGGAGATACCGTGCGGTGCTTTAGTTGTCATGCAGCTGTAGATAGA Consensus (163) 
 
Section 5 
TGGCAATATGGAGACTCAGCAGTTGGAAGACACAGGAAAGTATCCCCAAATTGC L1309 (217) 
TGGCAATATGGAGACTCAGCAGTTGGAAGACACAGGAAAGTATCCCCAAATTGC L1236 (217) 
TGGCAATATGGAGACTCAGCAGTTGGAAGACACAGGAAAGTATCCCCAAATTGC L591 (217) 
TGGCAATATGGAGACTCAGCAGTTGGAAGACACAGGAAAGTATCCCCAAATTGC L428 (217) 
TGGCAATATGGAGACTCAGCAGTTGGAAGACACAGGAAAGTATCCCCAAATTGC KMH2 (217) 
TGGCAATATGGAGACTCAGCAGTTGGAAGACACAGGAAAGTATCCCCAAATTGC 7159760 (217) 
TGGCAATATGGAGACTCAGCAGTTGGAAGACACAGGAAAGTATCCCCAAATTGC Consensus (217) 
 
Section 6 
AGATTTATCAACGGCTTTTATCTTGAAAATAGTGCCACGCAGTCTACAAATTCT L1309 (271) 
AGATTTATCAACGGCTTTTATCTTGAAAATAGTGCCACGCAGTCTACAAATTCT L1236 (271) 
AGATTTATCAACGGCTTTTATCTTGAAAATAGTGCCACGCAGTCTACAAATTCT L591 (271) 
AGATTTATCAACGGCTTTTATCTTGAAAATAGTGCCACGCAGTCTACAAATTCT L428 (271) 
AGATTTATCAACGGCTTTTATCTTGAAAATAGTGCCACGCAGTCTACAAATTCT KMH2 (271) 
AGATTTATCAACGGCTTTTATCTTGAAAATAGTGCCACGCAGTCTACAAATTCT 7159760 (271) 
AGATTTATCAACGGCTTTTATCTTGAAAATAGTGCCACGCAGTCTACAAATTCT Consensus (271) 
 
XIAP Alignment 
Section 7 
GGTATCCAGAATGGTCAGTACAAAGTTGAAAACTATCTGGGAAGCAGAGATCAT L1309 (325) 
GGTATCCAGAATGGTCAGTACAAAGTTGAAAACTATCTGGGAAGCAGAGATCAT L1236 (325) 
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GGTATCCAGAATGGTCAGTACAAAGTTGAAAACTATCTGGGAAGCAGAGATCAT L591 (325) 
GGTATCCAGAATGGTCAGTACAAAGTTGAAAACTATCTGGGAAGCAGAGATCAT L428 (325) 
GGTATCCAGAATGGTCAGTACAAAGTTGAAAACTATCTGGGAAGCAGAGATCAT KMH2 (325) 
GGTATCCAGAATGGTCAGTACAAAGTTGAAAACTATCTGGGAAGCAGAGATCAT 7159760 (325) 
GGTATCCAGAATGGTCAGTACAAAGTTGAAAACTATCTGGGAAGCAGAGATCAT Consensus (325) 
 
Section 8 
TTTGCCTTAGACAGGCCATCTGAGACACATGCAGACTATCTTTTGAGAACTGGG L1309 (379) 
TTTGCCTTAGACAGGCCATCTGAGACACATGCAGACTATCTTTTGAGAACTGGG L1236 (379) 
TTTGCCTTAGACAGGCCATCTGAGACACATGCAGACTATCTTTTGAGAACTGGG L591 (379) 
TTTGCCTTAGACAGGCCATCTGAGACACATGCAGACTATCTTTTGAGAACTGGG L428 (379) 
TTTGCCTTAGACAGGCCATCTGAGACACATGCAGACTATCTTTTGAGAACTGGG KMH2 (379) 
TTTGCCTTAGACAGGCCATCTGAGACACATGCAGACTATCTTTTGAGAACTGGG 7159760 (379) 
TTTGCCTTAGACAGGCCATCTGAGACACATGCAGACTATCTTTTGAGAACTGGG Consensus (379) 
 
Section 9 
CAGGTTGTAGATATATCAGACACCATATACCCGAGGAACCCTGCCATGTATAGT L1309 (433) 
CAGGTTGTAGATATATCAGACACCATATACCCGAGGAACCCTGCCATGTATAGT L1236 (433) 
CAGGTTGTAGATATATCAGACACCATATACCCGAGGAACCCTGCCATGTATAGT L591 (433) 
CAGGTTGTAGATATATCAGACACCATATACCCGAGGAACCCTGCCATGTATAGT L428 (433) 
CAGGTTGTAGATATATCAGACACCATATACCCGAGGAACCCTGCCATGTATAGT KMH2 (433) 
CAGGTTGTAGATATATCAGACACCATATACCCGAGGAACCCTGCCATGTATAGT 7159760 (433) 
CAGGTTGTAGATATATCAGACACCATATACCCGAGGAACCCTGCCATGTATAGT Consensus (433) 
 
Section 10 
GAAGAAGCTAGATTAAAGTCCTTTCAGAACTGGCCAGACTATGCTCACCTAACC L1309 (487) 
GAAGAAGCTAGATTAAAGTCCTTTCAGAACTGGCCAGACTATGCTCACCTAACC L1236 (487) 
GAAGAAGCTAGATTAAAGTCCTTTCAGAACTGGCCAGACTATGCTCACCTAACC L591 (487) 
GAAGAAGCTAGATTAAAGTCCTTTCAGAACTGGCCAGACTATGCTCACCTAACC L428 (487) 
GAAGAAGCTAGATTAAAGTCCTTTCAGAACTGGCCAGACTATGCTCACCTAACC KMH2 (487) 
GAAGAAGCTAGATTAAAGTCCTTTCAGAACTGGCCAGACTATGCTCACCTAACC 7159760 (487) 
GAAGAAGCTAGATTAAAGTCCTTTCAGAACTGGCCAGACTATGCTCACCTAACC Consensus (487) 
 
Section 11 
CCAAGAGAGTTAGCAAGTGCTGGACTCTACTACACAGGTATTGGTGACCAAGTG L1309 (541) 
CCAAGAGAGTTAGCAAGTGCTGGACTCTACTACACAGGTATTGGTGACCAAGTG L1236 (541) 
CCAAGAGAGTTAGCAAGTGCTGGACTCTACTACACAGGTATTGGTGACCAAGTG L591 (541) 
CCAAGAGAGTTAGCAAGTGCTGGACTCTACTACACAGGTATTGGTGACCAAGTG L428 (541) 
CCAAGAGAGTTAGCAAGTGCTGGACTCTACTACACAGGTATTGGTGACCAAGTG KMH2 (541) 
CCAAGAGAGTTAGCAAGTGCTGGACTCTACTACACAGGTATTGGTGACCAAGTG 7159760 (541) 
CCAAGAGAGTTAGCAAGTGCTGGACTCTACTACACAGGTATTGGTGACCAAGTG Consensus (541) 
 
Section 12 
CAGTGCTTTTGTTGTGGTGGAAAACTGAAAAATTGGGAACCTTGTGATCGTGCC L1309 (595) 
CAGTGCTTTTGTTGTGGTGGAAAACTGAAAAATTGGGAACCTTGTGATCGTGCC L1236 (595) 
CAGTGCTTTTGTTGTGGTGGAAAACTGAAAAATTGGGAACCTTGTGATCGTGCC L591 (595) 
CAGTGCTTTTGTTGTGGTGGAAAACTGAAAAATTGGGAACCTTGTGATCGTGCC L428 (595) 
CAGTGCTTTTGTTGTGGTGGAAAACTGAAAAATTGGGAACCTTGTGATCGTGCC KMH2 (595) 
CAGTGCTTTTGTTGTGGTGGAAAACTGAAAAATTGGGAACCTTGTGATCGTGCC 7159760 (595) 
CAGTGCTTTTGTTGTGGTGGAAAACTGAAAAATTGGGAACCTTGTGATCGTGCC Consensus (595) 
XIAP Alignment 
Section 13 
TGGTCAGAACACAGGCGACACTTTCCTAATTGCTTCTTTGTTTTGGGCCGGAAT L1309 (649) 
TGGTCAGAACACAGGCGACACTTTCCTAATTGCTTCTTTGTTTTGGGCCGGAAT L1236 (649) 
TGGTCAGAACACAGGCGACACTTTCCTAATTGCTTCTTTGTTTTGGGCCGGAAT L591 (649) 
TGGTCAGAACACAGGCGACACTTTCCTAATTGCTTCTTTGTTTTGGGCCGGAAT L428 (649) 
TGGTCAGAACACAGGCGACACTTTCCTAATTGCTTCTTTGTTTTGGGCCGGAAT KMH2 (649) 
TGGTCAGAACACAGGCGACACTTTCCTAATTGCTTCTTTGTTTTGGGCCGGAAT 7159760 (649) 
TGGTCAGAACACAGGCGACACTTTCCTAATTGCTTCTTTGTTTTGGGCCGGAAT Consensus (649) 
 
Section 14 
CTTAATATTCGAAGTGAATCTGATGCTGTGAGTTCTGATAGGAATTTCCCAAAT L1309 (703) 
CTTAATATTCGAAGTGAATCTGATGCTGTGAGTTCTGATAGGAATTTCCCAAAT L1236 (703) 
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CTTAATATTCGAAGTGAATCTGATGCTGTGAGTTCTGATAGGAATTTCCCAAAT L591 (703) 
CTTAATATTCGAAGTGAATCTGATGCTGTGAGTTCTGATAGGAATTTCCCAAAT L428 (703) 
CTTAATATTCGAAGTGAATCTGATGCTGTGAGTTCTGATAGGAATTTCCCAAAT KMH2 (703) 
CTTAATATTCGAAGTGAATCTGATGCTGTGAGTTCTGATAGGAATTTCCCAAAT 7159760 (703) 
CTTAATATTCGAAGTGAATCTGATGCTGTGAGTTCTGATAGGAATTTCCCAAAT Consensus (703) 
 
Section 15 
TCAACAAATCTTCCAAGAAATCCATCCATGGCAGATTATGAAGCACGGATCTTT L1309 (757) 
TCAACAAATCTTCCAAGAAATCCATCCATGGCAGATTATGAAGCACGGATCTTT L1236 (757) 
TCAACAAATCTTCCAAGAAATCCATCCATGGCAGATTATGAAGCACGGATCTTT L591 (757) 
TCAACAAATCTTCCAAGAAATCCATCCATGGCAGATTATGAAGCACGGATCTTT L428 (757) 
TCAACAAATCTTCCAAGAAATCCATCCATGGCAGATTATGAAGCACGGATCTTT KMH2 (757) 
TCAACAAATCTTCCAAGAAATCCATCCATGGCAGATTATGAAGCACGGATCTTT 7159760 (757) 
TCAACAAATCTTCCAAGAAATCCATCCATGGCAGATTATGAAGCACGGATCTTT Consensus (757) 
 
Section 16 
ACTTTTGGGACATGGATATACTCAGTTAACAAGGAGCAGCTTGCAAGAGCTGGA L1309 (811) 
ACTTTTGGGACATGGATATACTCAGTTAACAAGGAGCAGCTTGCAAGAGCTGGA L1236 (811) 
ACTTTTGGGACATGGATATACTCAGTTAACAAGGAGCAGCTTGCAAGAGCTGGA L591 (811) 
ACTTTTGGGACATGGATATACTCAGTTAACAAGGAGCAGCTTGCAAGAGCTGGA L428 (811) 
ACTTTTGGGACATGGATATACTCAGTTAACAAGGAGCAGCTTGCAAGAGCTGGA KMH2 (811) 
ACTTTTGGGACATGGATATACTCAGTTAACAAGGAGCAGCTTGCAAGAGCTGGA 7159760 (811) 
ACTTTTGGGACATGGATATACTCAGTTAACAAGGAGCAGCTTGCAAGAGCTGGA Consensus (811) 
 
Section 17 
TTTTATGCTTTAGGTGAAGGTGATAAAGTAAAGTGCTTTCACTGTGGAGGAGGG L1309 (865) 
TTTTATGCTTTAGGTGAAGGTGATAAAGTAAAGTGCTTTCACTGTGGAGGAGGG L1236 (865) 
TTTTATGCTTTAGGTGAAGGTGATAAAGTAAAGTGCTTTCACTGTGGAGGAGGG L591 (865) 
TTTTATGCTTTAGGTGAAGGTGATAAAGTAAAGTGCTTTCACTGTGGAGGAGGG L428 (865) 
TTTTATGCTTTAGGTGAAGGTGATAAAGTAAAGTGCTTTCACTGTGGAGGAGGG KMH2 (865) 
TTTTATGCTTTAGGTGAAGGTGATAAAGTAAAGTGCTTTCACTGTGGAGGAGGG 7159760 (865) 
TTTTATGCTTTAGGTGAAGGTGATAAAGTAAAGTGCTTTCACTGTGGAGGAGGG Consensus (865) 
 
Section 18 
CTAACTGATTGGAAGCCCAGTGAAGACCCTTGGGAACAACATGCTAAATGGTAT L1309 (919) 
CTAACTGATTGGAAGCCCAGTGAAGACCCTTGGGAACAACATGCTAAATGGTAT L1236 (919) 
CTAACTGATTGGAAGCCCAGTGAAGACCCTTGGGAACAACATGCTAAATGGTAT L591 (919) 
CTAACTGATTGGAAGCCCAGTGAAGACCCTTGGGAACAACATGCTAAATGGTAT L428 (919) 
CTAACTGATTGGAAGCCCAGTGAAGACCCTTGGGAACAACATGCTAAATGGTAT KMH2 (919) 
CTAACTGATTGGAAGCCCAGTGAAGACCCTTGGGAACAACATGCTAAATGGTAT 7159760 (919) 
CTAACTGATTGGAAGCCCAGTGAAGACCCTTGGGAACAACATGCTAAATGGTAT Consensus (919) 
 
XIAP Alignment 
Section 19 
  
CCAGGGTGCAAATATCTGTTAGAACAGAAGGGACAAGAATATATAAACAATATT L1309 (973) 
CCAGGGTGCAAATATCTGTTAGAACAGAAGGGACAAGAATATATAAACAATATT L1236 (973) 
CCAGGGTGCAAATATCTGTTAGAACAGAAGGGACAAGAATATATAAACAATATT L591 (973) 
CCAGGGTGCAAATATCTGTTAGAACAGAAGGGACAAGAATATATAAACAATATT L428 (973) 
CCAGGGTGCAAATATCTGTTAGAACAGAAGGGACAAGAATATATAAACAATATT KMH2 (973) 
CCAGGGTGCAAATATCTGTTAGAACAGAAGGGACAAGAATATATAAACAATATT 7159760 (973) 
CCAGGGTGCAAATATCTGTTAGAACAGAAGGGACAAGAATATATAAACAATATT Consensus (973) 
 
Section 20 
CATTTAACTCATTCACTTGAGGAGTGTCTGGTAAGAACTACTGAGAAAACACCA L1309 (1027) 
CATTTAACTCATTCACTTGAGGAGTGTCTGGTAAGAACTACTGAGAAAACACCA L1236 (1027) 
CATTTAACTCATTCACTTGAGGAGTGTCTGGTAAGAACTACTGAGAAAACACCA L591 (1027) 
CATTTAACTCATTCACTTGAGGAGTGTCTGGTAAGAACTACTGAGAAAACACCA L428 (1027) 
CATTTAACTCATTCACTTGAGGAGTGTCTGGTAAGAACTACTGAGAAAACACCA KMH2 (1027) 
CATTTAACTCATTCACTTGAGGAGTGTCTGGTAAGAACTACTGAGAAAACACCA 7159760 (1027) 
CATTTAACTCATTCACTTGAGGAGTGTCTGGTAAGAACTACTGAGAAAACACCA Consensus (1027) 
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Section 21 
TCACTAACTAGAAGAATTGATGATACCATCTTCCAAAATCCTATGGTACAAGAA L1309 (1081) 
TCACTAACTAGAAGAATTGATGATACCATCTTCCAAAATCCTATGGTACAAGAA L1236 (1081) 
TCACTAACTAGAAGAATTGATGATACCATCTTCCAAAATCCTATGGTACAAGAA L591 (1081) 
TCACTAACTAGAAGAATTGATGATACCATCTTCCAAAATCCTATGGTACAAGAA L428 (1081) 
TCACTAACTAGAAGAATTGATGATACCATCTTCCAAAATCCTATGGTACAAGAA KMH2 (1081) 
TCACTAACTAGAAGAATTGATGATACCATCTTCCAAAATCCTATGGTACAAGAA 7159760 (1081) 
TCACTAACTAGAAGAATTGATGATACCATCTTCCAAAATCCTATGGTACAAGAA Consensus (1081) 
 
Section 22 
GCTATACGAATGGGGTTCAGTTTCAAGGACATTAAGAAAATAATGGAGGAAAAA L1309 (1135) 
GCTATACGAATGGGGTTCAGTTTCAAGGACATTAAGAAAATAATGGAGGAAAAA L1236 (1135) 
GCTATACGAATGGGGTTCAGTTTCAAGGACATTAAGAAAATAATGGAGGAAAAA L591 (1135) 
GCTATACGAATGGGGTTCAGTTTCAAGGACATTAAGAAAATAATGGAGGAAAAA L428 (1135) 
GCTATACGAATGGGGTTCAGTTTCAAGGACATTAAGAAAATAATGGAGGAAAAA KMH2 (1135) 
GCTATACGAATGGGGTTCAGTTTCAAGGACATTAAGAAAATAATGGAGGAAAAA 7159760 (1135) 
GCTATACGAATGGGGTTCAGTTTCAAGGACATTAAGAAAATAATGGAGGAAAAA Consensus (1135) 
 
Section 23 
ATTCAGATATCTGGGAGCAACTATAAATCACTTGAGGTTCTGGTTGCAGATCTA L1309 (1189) 
ATTCAGATATCTGGGAGCAACTATAAATCACTTGAGGTTCTGGTTGCAGATCTA L1236 (1189) 
ATTCAGATATCTGGGAGCAACTATAAATCACTTGAGGTTCTGGTTGCAGATCTA L591 (1189) 
ATTCAGATATCTGGGAGCAACTATAAATCACTTGAGGTTCTGGTTGCAGATCTA L428 (1189) 
ATTCAGATATCTGGGAGCAACTATAAATCACTTGAGGTTCTGGTTGCAGATCTA KMH2 (1189) 
ATTCAGATATCTGGGAGCAACTATAAATCACTTGAGGTTCTGGTTGCAGATCTA 7159760 (1189) 
ATTCAGATATCTGGGAGCAACTATAAATCACTTGAGGTTCTGGTTGCAGATCTA Consensus (1189) 
 
Section 24 
GTGAATGCTCAGAAAGACAGTATGCCAGATGAGTCAAGTCAGACTTCATTACAG L1309 (1243) 
GTGAATGCTCAGAAAGACAGTATGCCAGATGAGTCAAGTCAGACTTCATTACAG L1236 (1243) 
GTGAATGCTCAGAAAGACAGTATGCCAGATGAGTCAAGTCAGACTTCATTACAG L591 (1243) 
GTGAATGCTCAGAAAGACAGTATGCCAGATGAGTCAAGTCAGACTTCATTACAG L428 (1243) 
GTGAATGCTCAGAAAGACAGTATGCCAGATGAGTCAAGTCAGACTTCATTACAG KMH2 (1243) 
GTGAATGCTCAGAAAGACAGTATGCAAGATGAGTCAAGTCAGACTTCATTACAG 7159760 (1243) 
GTGAATGCTCAGAAAGACAGTATGCCAGATGAGTCAAGTCAGACTTCATTACAG Consensus (1243) 
 
XIAP Alignment 
Section 25 
AAAGAGATTAGTACTGAAGAGCAGCTAAGGCGCCTGCAAGAGGAGAAGCTTTGC L1309 (1297) 
AAAGAGATTAGTACTGAAGAGCAGCTAAGGCGCCTGCAAGAGGAGAAGCTTTGC L1236 (1297) 
AAAGAGATTAGTACTGAAGAGCAGCTAAGGCGCCTGCAAGAGGAGAAGCTTTGC L591 (1297) 
AAAGAGATTAGTACTGAAGAGCAGCTAAGGCGCCTGCAAGAGGAGAAGCTTTGC L428 (1297) 
AAAGAGATTAGTACTGAAGAGCAGCTAAGGCGCCTGCAAGAGGAGAAGCTTTGC KMH2 (1297) 
AAAGAGATTAGTACTGAAGAGCAGCTAAGGCGCCTGCAAGAGGAGAAGCTTTGC 7159760 (1297) 
AAAGAGATTAGTACTGAAGAGCAGCTAAGGCGCCTGCAAGAGGAGAAGCTTTGC Consensus (1297) 
 
Section 26 
AAAATCTGTATGGATAGAAATATTGCTATCGTTTTTGTTCCTTGTGGACATCTA L1309 (1351) 
AAAATCTGTATGGATAGAAATATTGCTATCGTTTTTGTTCCTTGTGGACATCTA L1236 (1351) 
AAAATCTGTATGGATAGAAATATTGCTATCGTTTTTGTTCCTTGTGGACATCTA L591 (1351) 
AAAATCTGTATGGATAGAAATATTGCTATCGTTTTTGTTCCTTGTGGACATCTA L428 (1351) 
AAAATCTGTATGGATAGAAATATTGCTATCGTTTTTGTTCCTTGTGGACATCTA KMH2 (1351) 
AAAATCTGTATGGATAGAAATATTGCTATCGTTTTTGTTCCTTGTGGACATCTA 7159760 (1351) 
AAAATCTGTATGGATAGAAATATTGCTATCGTTTTTGTTCCTTGTGGACATCTA Consensus (1351) 
 
Section 27 
GTCACTTGTAAACAATGTGCTGAAGCAGTTGACAAGTGTCCCATGTGCTACACA L1309 (1405) 
GTCACTTGTAAACAATGTGCTGAAGCAGTTGACAAGTGTCCCATGTGCTACACA L1236 (1405) 
GTCACTTGTAAACAATGTGCTGAAGCAGTTGACAAGTGTCCCATGTGCTACACA L591 (1405) 
GTCACTTGTAAACAATGTGCTGAAGCAGTTGACAAGTGTCCCATGTGCTACACA L428 (1405) 
GTCACTTGTAAACAATGTGCTGAAGCAGTTGACAAGTGTCCCATGTGCTACACA KMH2 (1405) 
GTCACTTGTAAACAATGTGCTGAAGCAGTTGACAAGTGTCCCATGTGCTACACA 7159760 (1405) 
GTCACTTGTAAACAATGTGCTGAAGCAGTTGACAAGTGTCCCATGTGCTACACA Consensus (1405) 
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Section 28 
GTCATTACTTTCAAGCAAAAAATTTTTATGTCTTAA L1309 (1459) 
GTCATTACTTTCAAGCAAAAAATTTTTATGTCTTAA L1236 (1459) 
GTCATTACTTTCAAGCAAAAAATTTTTATGTCTTAA L591 (1459) 
GTCATTACTTTCAAGCAAAAAATTTTTATGTCTTAA L428 (1459) 
GTCATTACTTTCAAGCAAAAAATTTTTATGTCTTAA KMH2 (1459) 
GTCATTACTTTCAAGCAAAAAATTTTTATGTCTTAA 7159760 (1459) 
GTCATTACTTTCAAGCAAAAAATTTTTATGTCTTAA Consensus (1459) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Caspase-3 Alignment 
Section 1 
ATGGAGAACACTGAAAACTCAGTGGATTCAAAATCCATTAAAAATTTGGAACCA L1309 (1) 
ATGGAGAACACTGAAAACTCAGTGGATTCAAAATCCATTAAAAATTTGGAACCA L1236 (1) 
ATGGAGAACACTGAAAACTCAGTGGATTCAAAATCCATTAAAAATTTGGAACCA L591 (1) 
ATGGAGAACACTGAAAACTCAGTGGATTCAAAATCCATTAAAAATTTGGAACCA L428 (1) 
ATGGAGAACACTGAAAACTCAGTGGATTCAAAATCCATTAAAAATTTGGAACCA KMH2 (1) 
ATGGAGAACACTGAAAACTCAGTGGATTCAAAATCCATTAAAAATTTGGAACCA XM_003524 (1) 
ATGGAGAACACTGAAAACTCAGTGGATTCAAAATCCATTAAAAATTTGGAACCA Consensus (1) 
 
Section 2 
AAGATCATACATGGAAGCGAATCAATGGACTCTGGAATATCCCTGGACAACAGT L1309 (55) 
AAGATCATACATGGAAGCGAATCAATGGACTCTGGAATATCCCTGGACAACAGT L1236 (55) 
AAGATCATACATGGAAGCGAATCAATGGACTCTGGAATATCCCTGGACAACAGT L591 (55) 
AAGATCATACATGGAAGCGAATCAATGGACTCTGGAATATCCCTGGACAACAGT L428 (55) 
AAGATCATACATGGAAGCGAATCAATGGACTCTGGAATATCCCTGGACAACAGT KMH2 (55) 
AAGATCATACATGGAAGCGAATCAATGGACTCTGGAATATCCCTGGACAACAGT XM_003524 (55) 
AAGATCATACATGGAAGCGAATCAATGGACTCTGGAATATCCCTGGACAACAGT Consensus (55) 
 
Section 3 
TATAAAATGGATTATCCTGAGATGGGTTTATGTATAATAATTAATAATAAGAAT L1309 (109) 
TATAAAATGGATTATCCTGAGATGGGTTTATGTATAATAATTAATAATAAGAAT L1236 (109) 
TATAAAATGGATTATCCTGAGATGGGTTTATGTATAATAATTAATAATAAGAAT L591 (109) 
TATAAAATGGATTATCCTGAGATGGGTTTATGTATAATAATTAATAATAAGAAT L428 (109) 
TATAAAATGGATTATCCTGAGATGGGTTTATGTATAATAATTAATAATAAGAAT KMH2 (109) 
TATAAAATGGATTATCCTGAGATGGGTTTATGTATAATAATTAATAATAAGAAT XM_003524 (109) 
TATAAAATGGATTATCCTGAGATGGGTTTATGTATAATAATTAATAATAAGAAT Consensus (109) 
 
Section 4 
TTTCATAAAAGCACTGGAATGACATCTCGGTCTGGTACAGATGTCGATGCAGCA L1309 (163) 
TTTCATAAAAGCACTGGAATGACATCTCGGTCTGGTACAGATGTCGATGCAGCA L1236 (163) 
   Appendix 
 78
TTTCATAAAAGCACTGGAATGACATCTCGGTCTGGTACAGATGTCGATGCAGCA L591 (163) 
TTTCATAAAAGCACTGGAATGACATCTCGGTCTGGTACAGATGTCGATGCAGCA L428 (163) 
TTTCATAAAAGCACTGGAATGACATCTCGGTCTGGTACAGATGTCGATGCAGCA KMH2 (163) 
TTTCATAAAAGCACTGGAATGACATCTCGGTCTGGTACAGATGTCGATGCAGCA XM_003524 (163) 
TTTCATAAAAGCACTGGAATGACATCTCGGTCTGGTACAGATGTCGATGCAGCA Consensus (163) 
 
Section 5 
AACCTCAGGGAAACATTCAGAAACTTGAAATATGAAGTCAGGAATAAAAATGAT L1309 (217) 
AACCTCAGGGAAACATTCAGAAACTTGAAATATGAAGTCAGGAATAAAAATGAT L1236 (217) 
AACCTCAGGGAAACATTCAGAAACTTGAAATATGAAGTCAGGAATAAAAATGAT L591 (217) 
AACCTCAGGGAAACATTCAGAAACTTGAAATATGAAGTCAGGAATAAAAATGAT L428 (217) 
AACCTCAGGGAAACATTCAGAAACTTGAAATATGAAGTCAGGAATAAAAATGAT KMH2 (217) 
AACCTCAGGGAAACATTCAGAAACTTGAAATATGAAGTCAGGAATAAAAATGAT XM_003524 (217) 
AACCTCAGGGAAACATTCAGAAACTTGAAATATGAAGTCAGGAATAAAAATGAT Consensus (217) 
 
Section 6 
CTTACACGTGAAGAAATTGTGGAATTGATGCGTGATGTTTCTAAAGAAGATCAC L1309 (271) 
CTTACACGTGAAGAAATTGTGGAATTGATGCGTGATGTTTCTAAAGAAGATCAC L1236 (271) 
CTTACACGTGAAGAAATTGTGGAATTGATGCGTGATGTTTCTAAAGAAGATCAC L591 (271) 
CTTACACGTGAAGAAATTGTGGAATTGATGCGTGATGTTTCTAAAGAAGATCAC L428 (271) 
CTTACACGTGAAGAAATTGTGGAATTGATGCGTGATGTTTCTAAAGAAGATCAC KMH2 (271) 
CTTACACGTGAAGAAATTGTGGAATTGATGCGTGATGTTTCTAAAGAAGATCAC XM_003524 (271) 
CTTACACGTGAAGAAATTGTGGAATTGATGCGTGATGTTTCTAAAGAAGATCAC Consensus (271) 
 
Caspase-3 Alignment 
Section 7 
AGCAAAAGGAGCAGTTTTGTTTGTGTGCTTCTGAGCCATGGTGAAGAAGGAATA L1309 (325) 
AGCAAAAGGAGCAGTTTTGTTTGTGTGCTTCTGAGCCATGGTGAAGAAGGAATA L1236 (325) 
AGCAAAAGGAGCAGTTTTGTTTGTGTGCTTCTGAGCCATGGTGAAGAAGGAATA L591 (325) 
AGCAAAAGGAGCAGTTTTGTTTGTGTGCTTCTGAGCCATGGTGAAGAAGGAATA L428 (325) 
AGCAAAAGGAGCAGTTTTGTTTGTGTGCTTCTGAGCCATGGTGAAGAAGGAATA KMH2 (325) 
AGCAAAAGGAGCAGTTTTGTTTGTGTGCTTCTGAGCCATGGTGAAGAAGGAATA XM_003524 (325) 
AGCAAAAGGAGCAGTTTTGTTTGTGTGCTTCTGAGCCATGGTGAAGAAGGAATA Consensus (325) 
 
Section 8 
ATTTTTGGAACAAATGGACCTGTTGACCTGAAAAAAATAACAAACTTTTTCAGA L1309 (379) 
ATTTTTGGAACAAATGGACCTGTTGACCTGAAAAAAATAACAAACTTTTTCAGA L1236 (379) 
ATTTTTGGAACAAATGGACCTGTTGACCTGAAAAAAATAACAAACTTTTTCAGA L591 (379) 
ATTTTTGGAACAAATGGACCTGTTGACCTGAAAAAAATAACAAACTTTTTCAGA L428 (379) 
ATTTTTGGAACAAATGGACCTGTTGACCTGAAAAAAATAACAAACTTTTTCAGA KMH2 (379) 
ATTTTTGGAACAAATGGACCTGTTGACCTGAAAAAAATAACAAACTTTTTCAGA XM_003524 (379) 
ATTTTTGGAACAAATGGACCTGTTGACCTGAAAAAAATAACAAACTTTTTCAGA Consensus (379) 
 
Section 9 
GGGGATCGTTGTAGAAGTCTAACTGGAAAACCCAAACTTTTCATTATTCAGGCC L1309 (433) 
GGGGATCGTTGTAGAAGTCTAACTGGAAAACCCAAACTTTTCATTATTCAGGCC L1236 (433) 
GGGGATCGTTGTAGAAGTCTAACTGGAAAACCCAAACTTTTCATTATTCAGGCC L591 (433) 
GGGGATCGTTGTAGAAGTCTAACTGGAAAACCCAAACTTTTCATTATTCAGGCC L428 (433) 
GGGGATCGTTGTAGAAGTCTAACTGGAAAACCCAAACTTTTCATTATTCAGGCC KMH2 (433) 
GGGGATCGTTGTAGAAGTCTAACTGGAAAACCCAAACTTTTCATTATTCAGGCC XM_003524 (433) 
GGGGATCGTTGTAGAAGTCTAACTGGAAAACCCAAACTTTTCATTATTCAGGCC Consensus (433) 
 
Section 10 
TGCCGTGGTACAGAACTGGACTGTGGCATTGAGACAGACAGTGGTGTTGATGAT L1309 (487) 
TGCCGTGGTACAGAACTGGACTGTGGCATTGAGACAGACAGTGGTGTTGATGAT L1236 (487) 
TGCCGTGGTACAGAACTGGACTGTGGCATTGAGACAGACAGTGGTGTTGATGAT L591 (487) 
TGCCGTGGTACAGAACTGGACTGTGGCATTGAGACAGACAGTGGTGTTGATGAT L428 (487) 
TGCCGTGGTACAGAACTGGACTGTGGCATTGAGACAGACAGTGGTGTTGATGAT KMH2 (487) 
TGCCGTGGTACAGAACTGGACTGTGGCATTGAGACAGACAGTGGTGTTGATGAT XM_003524 (487) 
TGCCGTGGTACAGAACTGGACTGTGGCATTGAGACAGACAGTGGTGTTGATGAT Consensus (487) 
 
Section 11 
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GACATGGCGTGTCATAAAATACCAGTGGAGGCCGACTTCTTGTATGCATACTCC L1309 (541) 
GACATGGCGTGTCATAAAATACCAGTGGAGGCCGACTTCTTGTATGCATACTCC L1236 (541) 
GACATGGCGTGTCATAAAATACCAGTGGAGGCCGACTTCTTGTATGCATACTCC L591 (541) 
GACATGGCGTGTCATAAAATACCAGTGGAGGCCGACTTCTTGTATGCATACTCC L428 (541) 
GACATGGCGTGTCATAAAATACCAGTGGAGGCCGACTTCTTGTATGCATACTCC KMH2 (541) 
GACATGGCGTGTCATAAAATACCAGTGGAGGCCGACTTCTTGTATGCATACTCC XM_003524 (541) 
GACATGGCGTGTCATAAAATACCAGTGGAGGCCGACTTCTTGTATGCATACTCC Consensus (541) 
 
Section 12 
ACAGCACCTGGTTATTATTCTTGGCGAAATTCAAAGGATGGCTCCTGGTTCATC L1309 (595) 
ACAGCACCTGGTTATTATTCTTGGCGAAATTCAAAGGATGGCTCCTGGTTCATC L1236 (595) 
ACAGCACCTGGTTATTATTCTTGGCGAAATTCAAAGGATGGCTCCTGGTTCATC L591 (595) 
ACAGCACCTGGTTATTATTCTTGGCGAAATTCAAAGGATGGCTCCTGGTTCATC L428 (595) 
ACAGCACCTGGTTATTATTCTTGGCGAAATTCAAAGGATGGCTCCTGGTTCATC KMH2 (595) 
ACAGCACCTGGTTATTATTCTTGGCGAAATTCAAAGGATGGCTCCTGGTTCATC XM_003524 (595) 
ACAGCACCTGGTTATTATTCTTGGCGAAATTCAAAGGATGGCTCCTGGTTCATC Consensus (595) 
Caspase-3 Alignment 
Section 13 
CAGTCGCTTTGTGCCATGCTGAAACAGTATGCCGACAAGCTTGAATTTATGCAC L1309 (649) 
CAGTCGCTTTGTGCCATGCTGAAACAGTATGCCGACAAGCTTGAATTTATGCAC L1236 (649) 
CAGTCGCTTTGTGCCATGCTGAAACAGTATGCCGACAAGCTTGAATTTATGCAC L591 (649) 
CAGTCGCTTTGTGCCATGCTGAAACAGTATGCCGACAAGCTTGAATTTATGCAC L428 (649) 
CAGTCGCTTTGTGCCATGCTGAAACAGTATGCCGACAAGCTTGAATTTATGCAC KMH2 (649) 
CAGTCGCTTTGTGCCATGCTGAAACAGTATGCCGACAAGCTTGAATTTATGCAC XM_003524 (649) 
CAGTCGCTTTGTGCCATGCTGAAACAGTATGCCGACAAGCTTGAATTTATGCAC Consensus (649) 
 
Section 14 
ATTCTTACCCGGGTTAACCGAAAGGTGGCAACAGAATTTGAGTCCTTTTCCTTT L1309 (703) 
ATTCTTACCCGGGTTAACCGAAAGGTGGCAACAGAATTTGAGTCCTTTTCCTTT L1236 (703) 
ATTCTTACCCGGGTTAACCGAAAGGTGGCAACAGAATTTGAGTCCTTTTCCTTT L591 (703) 
ATTCTTACCCGGGTTAACCGAAAGGTGGCAACAGAATTTGAGTCCTTTTCCTTT L428 (703) 
ATTCTTACCCGGGTTAACCGAAAGGTGGCAACAGAATTTGAGTCCTTTTCCTTT KMH2 (703) 
ATTCTTACCCGGGTTAACCGAAAGGTGGCAACAGAATTTGAGTCCTTTTCCTTT XM_003524 (703) 
ATTCTTACCCGGGTTAACCGAAAGGTGGCAACAGAATTTGAGTCCTTTTCCTTT Consensus (703) 
 
Section 15 
GACGCTACTTTTCATGCAAAGAAACAGATTCCATGTATTGTTTCCATGCTCACA L1309 (757) 
GACGCTACTTTTCATGCAAAGAAACAGATTCCATGTATTGTTTCCATGCTCACA L1236 (757) 
GACGCTACTTTTCATGCAAAGAAACAGATTCCATGTATTGTTTCCATGCTCACA L591 (757) 
GACGCTACTTTTCATGCAAAGAAACAGATTCCATGTATTGTTTCCATGCTCACA L428 (757) 
GACGCTACTTTTCATGCAAAGAAACAGATTCCATGTATTGTTTCCATGCTCACA KMH2 (757) 
GACGCTACTTTTCATGCAAAGAAACAGATTCCATGTATTGTTTCCATGCTCACA XM_003524 (757) 
GACGCTACTTTTCATGCAAAGAAACAGATTCCATGTATTGTTTCCATGCTCACA Consensus (757) 
 
Section 16 
AAAGAACTCTATTTTTATCACTAA L1309 (811) 
AAAGAACTCTATTTTTATCACTAA L1236 (811) 
AAAGAACTCTATTTTTATCACTAA L591 (811) 
AAAGAACTCTATTTTTATCACTAA L428 (811) 
AAAGAACTCTATTTTTATCACTAA KMH2 (811) 
AAAGAACTCTATTTTTATCACTAA XM_003524 (811) 
AAAGAACTCTATTTTTATCACTAA Consensus (811) 
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Summary 
Apoptosis represents an efficient mechanism to eliminate unwanted cells and is 
carried out by a family of cysteine containing aspartate-specific proteases, termed 
capases. Suppression of caspases leads to defective apoptosis and contributes to 
the pathogenesis of cancer by several mechanisms. The Hodgkin and Reed-
Sternberg cell (H-RS)  is a malignant germinal center B cell with rearranged but 
nonproductive immunoglobulin genes. However, through yet unknown mechanisms, 
H-RS cells resist the apoptotic fate normally suffered by defective B cells with 
crippled immunoglobulin genes. The H-RS cells were previously shown to be 
resistant to CD95-induced apoptosis. In this work, the intracellular events after 
induction of the mitochondrial apoptosis pathway have been scrutinized. The data 
provided show that Hodgkin's disease derived (HD) B cell lines are uniformly 
resistant to staurosporine, a protein kinase C inhibitor that preferentially stimulates 
the mitochondrial apoptotic pathway. Staurosporine failed to induce cytochrome c 
release from mitochondria in HD B cells and correspondingly, activation of caspases 
was not observed. In staurosporine-treated Hodgkin cells, Bax, a pro-apoptotic Bcl-2 
family member, remained in its inactive state, indicating that these cell lines have a 
defect in this crucial step in apoptotic signaling upstream of the mitochondria. Further 
analysis of the caspase cascade downstream of mitochondria, showed that addition 
of cytochrome c failed to stimulate caspase-3 activation in cytosolic extracts of HD B 
cell lines. This appeared to be due to the overexpression of the X-linked inhibitor of 
apoptosis (XIAP) in these cell lines. Co-immunoprecipitation studies revealed that 
XIAP constitutively bound to caspase-3 and prevents the proteolytic processing of 
caspase-3 required for its activation. Removal of XIAP by either, addition of a XIAP-
inhibitor Smac, or by immunodepletion, restored cytochrome c-triggered processing 
and activation of caspase-3. Finally, XIAP also inhibits caspase-9 in HD B cell lines, 
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suggesting a dual inhibitory role of XIAP in these cell lines, first by acting as a 
caspase-9 inhibitor and blocking of the initial cleavage of caspase-3, and then by 
inhibiting caspase-3 enzymatic activity and its maturation. In summary, defects in two 
crucial steps of the mitochondrial apoptotic pathway have been identified in H-RS 
cells that result in the complete abrogation of this pathway. Many of the drugs used 
for chemotherapy converge at the mitochondrial site of apoptosis and induce 
apoptosis by promoting the efflux of mitochondrial pro-apoptotic factors into the 
cytosol followed by activation of caspase cascades downstream of mitochondria. 
Defective mitochondrial apoptotic pathways contribute to resistance against multiple 
apoptotic stimuli, which may explain the resistance of H-RS cells against immune 
surveillance and chemotherapy at late stage of disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Zusammenfassung 
 83
Zusammenfassung 
 
Apoptose, auch als programmierter Zelltod bezeichnet, ist ein essentieller 
Mechanismus zur Aufrechterhaltung der Gewebehomöastasis und steht damit der 
Zellteilung als negativ regulierender Mechanismus gegenüber. Während der 
Apoptose aktiviert die Zelle ein internes Zerstörungsprogramm, dessen 
charakteristische Merkmale Veränderungen an der Plasmamembran (membrane 
blebbing), die Kondensierung des Zellkernes, der Abbau der Kern-DNA, sowie die 
darauf folgende Phagozytose der Zellreste durch Nachbarzellen ohne 
Entzündungsreaktion,  sind. Im vielzelligen Organismus ist die Apoptose ein 
natürlicher Bestandteil der Ontogenese und unter anderem an der Entwicklung der 
Organe beteiligt, außerdem an der Beseitigung von gealterten, sowie infizierten oder 
mutierten Zellen. Somit wird durch die Apoptose eine effiziente Elimination von 
unerwünschten Zellen erreicht, und ihre Inhibition trägt zur Pathogenese 
verschiedener Erkrankungen bei, unter anderem zur Karzinogenese. Die 
Haupteffektoren der Apoptose sind Aspartat-spezifische Proteasen, die sogenannten 
Caspasen. Die Aktivierung von Caspasen kann durch mindestens zwei 
Apoptosesignalwege stattfinden: Zum einen kann ein Signalweg durch die 
Aktivierung der TNF- (Tumor necrosis factor) Rezeptorfamilie durch ihre spezifischen 
Liganden eingeleitet werden. Dies führt zur Rekrutierung und Aktivierung von 
Caspase-8, welche ihrerseits Caspase-3 aktiviert. Aktivierte Caspase-3 degradiert 
Apoptose-spezifische Substrate in der Zelle und führt damit zum Abbau der Zelle in 
den späten Schritten der Apoptose. Im zweiten Signalweg spielen Mitochondrien 
eine zentrale Rolle. Die Aktivierung des mitochondrialen Apoptosesignalweges wird 
durch Proteine der Bcl-2-Familie reguliert. Diese Proteinfamilie besteht aus anti-
apoptotischen sowie pro-apoptotischen Proteinen, von denen Bax das bislang 
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bestuntersuchte pro-apoptotische Protein darstellt. Im Falle eines apoptotischen 
Stimulus findet eine allosterische Konformationsänderung des Bax-Proteins statt, 
welche zur Verankerung des Proteins in der mitochondrialen Außenmembran und 
seiner Oligomerisierung führt. Durch diese Oligomere werden pro-apoptotischen 
Moleküle aus Mitochondrien ins Zytosol freigesetzt, zum Beispiel Cytochrom c und 
Smac (second mitochondria-derived activator of caspases). Das zytosolische 
Cytochrom c initiiert die Formierung des Apoptosoms, das aus Apaf-1, Caspase-9 
und Cytochrom c besteht. Die rekrutierte Caspase-9 wird im Apoptosom aktiviert und 
kann anschließend Caspase-3 aktivieren. Aktive Caspase-3 degradiert gezielt 
spezifische zelluläre Substrate und führt damit zum Tod der Zelle.  
 
Die maligne Hodgkin-Reed-Sternberg (H-RS)-Zelle ist ein Keimzentrums-B-
Lymphozyt mit rearrangierten aber nicht produktiven Immunglobulin-Gensegmenten. 
Durch einen bislang unbekannten Mechanismus gelingt es der H-RS-Zelle, der 
Apoptose, die normalerweise eine B-Zelle mit nicht-produktiven Immunglobulingenen 
eliminiert, zu entkommen. Vier Hodgkin-Zelllinien, aus Geweben von Hodgkin-
Patienten etabliert, wurden in der vorliegenden Arbeit im Hinblick auf Defekte von 
apoptotischen Signalwegen untersucht. Bereits publizierte Untersuchungen zur 
Apoptose in diesen Zelllinien zeigten eine allgemeine Apoptoseresistenz. Auf Grund 
der Resistenz gegenüber der Apoptose-Induktion durch Fas-Ligand wurde ein Defekt 
des Rezeptor-vermittelten Signalweges der Apoptose postuliert. 
In der vorliegenden Arbeit wurden die intrazellulären Signalwege der Apoptose nach 
Induktion mit Staurosporin, einem Induktor des mitochondrialen 
Apoptosesignalweges, untersucht. Diese Untersuchungen zeigten eine generelle 
Resistenz der H-RS-Zelllinien gegen Staurosporin-induzierten Zelltod. Die detailierte 
Analyse des mitochondrialen Apoptosesignalweges führte zur Entdeckung von zwei 
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Defekten. Zum einen wurde ein Defekt im Signalweg oberhalb von Mitochondrien 
charakterisiert, der zur Inhibition der Konformationsänderung von Bax führte. Nicht 
aktiviertes Bax kann jedoch die Freisetzung von Cytochrom c aus Mitochondrien 
nicht induzieren. Folglich wird auch die anschließende Caspasekaskade und damit 
die Apoptose nicht initiiert. Zur weiteren Analyse der Caspasekaskade wurden 
zytosolische Fraktionen von Zellen isoliert und die Caspaseaktivität nach der Zugabe 
von Cytochrom c in vitro untersucht. Diese Untersuchungen ergaben, dass die 
Hodgkin-Zellen in einem zweiten Signalschritt defekt sind, die Cytochrom c-
vermittelte Caspaseaktivierung ist vollständig inhibiert. Die Prozessierung und 
Aktivierung von Caspase-9 und Caspase-3 sind blockiert und als Folge davon wurde 
keine Caspaseaktivität detektiert. Diesem zweiten Defekt im apoptotischen 
Signalweg in Hodgkin-Zelllinien liegt die Überexpression von XIAP (X-linked Inhibitor 
of Apoptosis), einem Protein der IAP-Familie (Inhibitors of Apoptosis), zu Grunde. 
Die IAP-Proteine sind Inhibitoren der Apoptose, die ihre Funktion durch direkte 
Interaktion mit Caspasen ausüben. Die vorliegenden Daten zeigen, dass XIAP mit 
Caspase-3 assoziiert ist und damit die Aktivierung und Aktivität von Caspase-3 
inhibiert. Die Depletion von  XIAP hingegen resultierte in der Wiederherstellung der 
Caspaseaktivität. Auch in Gegenwart des Proteins Smac, das an XIAP bindet und 
seine Funktion blockiert, war die Caspaseaktivität wieder hergestellt. Diese 
Ergebnisse weisen auf eine zentrale Rolle von XIAP in der Inhibition der 
Caspasekaskade in H-RS-Zelllinien hin.  
Zusammenfassend zeigt die vorliegende Arbeit, dass in H-RS-Zelllinien zwei Defekte 
in intrazellulären Signalwegen zur vollständigen Inhibition der Apoptose führen. 
Während sich der eine Defekt in der Signalkette oberhalb von Mitochondrien, im Bax-
Aktivierungsschritt, befindet, liegt der zweite Defekt im Signalweg unterhalb der 
Mitochondrien in der Inhibition der Caspaseaktivierungskaskade durch die 
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Überexpression von XIAP. Das Vorliegen mehrerer Defekte in Apoptosesignalwegen 
von Hodgkin-Zellen erklärt ihre Resistenz gegen Immunabwehr und Chemotherapie.   
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